Introduction {#s1}
============

Muscarinic acetylcholine receptors contain an orthosteric site and a topographically distinct allosteric site ([@bib13]; [@bib17]). The latter is located at the extracellular surface within a vestibule to the orthosteric site ([@bib12]), and that region shows comparatively low sequence homology among the five muscarinic subtypes (M~1~--M~5~). The allosteric site therefore is more subtype-specific than the orthosteric site, and allosteric ligands are increasingly of interest for their therapeutic potential ([@bib11]). Owing to the early demonstration of allosteric interactions in muscarinic systems ([@bib3]; [@bib29]) and the variety of available modulators ([@bib17]), the M~2~ muscarinic receptor has been a prototype for such effects within the broader family of G protein-coupled receptors (GPCRs).

Most studies of the interaction of an allosteric ligand with the allosteric site have been based on the modulation of events at the orthosteric site, typically on receptors in native membranes or detergent-solubilized extracts. Such events may be measured directly, as in the binding of a radiolabeled antagonist ([@bib2]), or they may be inferred from functional consequences such as the turnover of \[^35^S\]GTP*γ*S ([@bib17]). They also may be positive or negative ([@bib17]), and the data generally have been described in terms of interactions between two binding sites on a monomeric receptor ([@bib2]).

In the case of the M~2~ receptor, an atomic-level view of the interaction within a monomer has emerged recently from the crystallography-derived structure of a biliganded receptor ([@bib12]) and from inferences based on molecular dynamics simulations ([@bib5]). Although such results offer an explanation for negative cooperativity at the atomic level, the mechanism of action of positive modulators such as strychnine remains unclear ([@bib5]). That uncertainty relates to questions regarding electrostatic repulsion between highly charged allosteric and orthosteric ligands, steric effects of the former on binding of the latter, and the effect of either ligand on conformational stability at the site of the other ([@bib5]).

The common view that allosteric interactions occur within monomeric receptors is limited in its ability to rationalize complex effects that are seen in the binding of radioligands. For example, dissociation of the antagonist \[^3^H\]quinuclidinylbenzilate (QNB) from the M~2~ receptor is accelerated by gallamine at lower concentrations of the allosteric ligand and slowed at higher concentrations, resulting in a bell-shaped profile ([@bib6]). At equilibrium, the binding of \[^3^H\]QNB and the inverse agonist *N*-\[^3^H\]methylscopolamine (NMS) can display a biphasic and even a triphasic dependence on the concentration of an allosteric modulator ([@bib23]; [@bib28]). Such effects imply either that a single molecule of the receptor possesses up to four allosteric sites or that allostery occurs via linked sites within an oligomer ([@bib23]; [@bib28]).

To understand how a multimeric complex might account for allosteric behavior that resists explanation in terms of monomers, we have compared positive and negative allosteric modulators for their effects on oligomers and purified monomers of the M~2~ muscarinic receptor. Our approach has involved a novel FRET-based sensor of conformation at the allosteric site, mutants that allow only for allosteric modulation between linked protomers, mechanistic modeling, and molecular dynamics simulations. Taken together, the results indicate that intramolecular interactions---*i.e*., between two sites on a monomer or on the same protomer of an oligomer---are dominated by electrostatic repulsion and result in low-affinity negative modulation by the allosteric ligand. Intermolecular interactions---*i.e*., between two sites on neighboring protomers of an oligomer---result in high-affinity allosteric modulation that may be positive or negative, depending upon the constraints associated with ligand-binding and the nature and extent of conformational changes transmitted between protomers. The results provide a direct demonstration of how allosteric effects characteristic of M~2~ receptors arise from interactions between the constituent protomers of an oligomer.

Results {#s2}
=======

Binding of allosteric modulators to monomers {#s2-1}
--------------------------------------------

M~2~ receptors were solubilized as oligomers and purified as monomers in the manner described previously ([@bib26]; [@bib27]). cMyc- and FLAG-tagged receptors were extracted from co-infected *Sf*9 cells in digitonin--cholate, and oligomers were detected by co-immunoprecipitation ([Figure 1A](#fig1){ref-type="fig"}). The solubilized preparation was applied to an affinity resin of immobilized aminobenztropane (ABT), and western blotting of the purified receptor with an anti-M~2~ antibody indicated that 97% of the immunopositive material migrated as a monomer. Eighty-three percent migrated as a monomer when the sample was cross-linked with BS^3^ ([Figure 1B](#fig1){ref-type="fig"} and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). The affinity of \[^3^H\]NMS for the purified monomer ([Equation 3](#equ4){ref-type="disp-formula"}, log *K* = −8.01 ± 0.04, *N* = 5) and the purity of the sample were the same as reported previously (cf. [@bib26]; [@bib27]).10.7554/eLife.11685.003Figure 1.Oligomeric and monomeric preparations of the M~2~ muscarinic receptor.(**A**) Gels were loaded with samples of FLAG- and c-Myc-tagged receptor extracted from co-infected *Sf*9 cells (lane 1, 20--30 fmol of receptor per lane) or from the precipitate obtained upon treatment of the extract with an immobilized anti-FLAG antibody (lane 2, 15--35 fmol of receptor per lane). The amount of receptor was determined from the binding of \[^3^H\]QNB at the saturating concentration of 10 nM. Following electrophoresis and transfer, the membranes were blotted with anti-c-Myc antibody. (**B**) Gels were loaded with parallel samples of purified M~2~ receptor taken before (lane 1) and after cross-linking with BS^3^ (lane 2). The same amount of receptor was applied to each well (15--25 fmol). The intensities of the immunopositive bands were measured by densitometry, and the area under each densitometric trace was determined in three segments as indicated by the braces (*a*, 40--75 kDa; *b*, 75--170 kDa; *c*, 170--360 kDa) ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}, *N* = 3). The monomeric receptor migrated as a doublet (\~44 kDa and 53 kDa). (**C**) The rate constant for the dissociation of \[^3^H\]QNB from purified monomers was measured at graded concentrations of gallamine (*k*~obsd~) and normalized to that in the absence of gallamine (*k*~0~) to obtain the relative rate constant (*k*~obsd~/*k*~0~) plotted on the *y*-axis. The data were analyzed in terms of [Equation 2](#equ2){ref-type="disp-formula"} to obtain the fitted curve shown in the figure (solid line) and the parametric values listed in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}. (**D**) \[^3^H\]NMS (10 nM) was mixed with gallamine at the concentrations shown on the *x*-axis, and binding was measured after incubation of the reaction mixture for 21 hr at 30°C. The solid line represents the best fit of [Equation 2](#equ2){ref-type="disp-formula"} (*n* = 1), and the fitted parametric values are listed in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}. The dashed lines in panels **C** and **D** are the fitted curves from similar experiments on preparations in which the M~2~ receptor is largely or wholly oligomeric (**C**, *Sf*9 membranes; **D**, *Sf*9 extracts) ([@bib28]). (**E--G**) The binding of \[^3^H\]NMS (10 nM) to M~2~ receptors extracted from porcine sarcolemmal membranes (**closed symbols**) and purified as monomers from *Sf*9 cells (**open symbols**) was measured at graded concentrations of strychnine following the simultaneous addition of both ligands (**E**), the sequential addition of strychnine and \[^3^H\]NMS (**F**), and the sequential addition of \[^3^H\]NMS and strychnine (**G**). The binding profiles obtained following simultaneous addition were identical after incubation of the samples for 3 hr and 21 hr, and the data obtained after 21 hr are shown in the figure. Pretreatment with one ligand was followed after 2 hr by the addition of the other and further incubation for 3 hr. The temperature of incubation was 30°C throughout. The solid lines in each panel depict the best fits of [Equation 2](#equ2){ref-type="disp-formula"} to the data from three experiments taken in concert, and the parametric values are listed in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.003](10.7554/eLife.11685.003)10.7554/eLife.11685.004Figure 1---source data 1.*Panel B***--**Monomeric status of the purified M~2~ receptor after chemical cross-linking.*Panel C*--Parametric values for the effect of gallamine on the rate of dissociation of \[^3^H\]QNB. *Panel D*--Parametric values for the effect of gallamine on the binding of \[^3^H\]NMS at equilibrium. *Panels E--G*--Parametric values for the effect of strychnine on the binding of \[^3^H\]NMS to oligomers and monomers.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.004](10.7554/eLife.11685.004)10.7554/eLife.11685.005Figure 1---source data 2.Figure 1--figure supplement 1--Parametric values for the effect of strychnine on the binding of \[^3^H\]NMS and \[^3^H\]QNB to membrane-bound M~2~ receptor.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.005](10.7554/eLife.11685.005)10.7554/eLife.11685.006Figure 1---source data 3.Figure 1-figure supplement 2--Rate constants for the simulated binding of strychnine and \[^3^H\]NMS according to [Figure 6](#fig6){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.006](10.7554/eLife.11685.006)10.7554/eLife.11685.007Figure 1---figure supplement 1.Effect of strychnine on the binding of \[^3^H\]NMS and \[^3^H\]QNB to membrane-bound M~2~receptor.The binding of \[^3^H\]NMS (**A**) or \[^3^H\]QNB (**B**) to M~2~ receptor in membranes from CHO cells was measured at the concentrations of strychnine shown on the x-axes. Strychnine and the radioligand were added simultaneously to the receptor, and the reaction mixture was incubated for 3 hr (○, •) and 12 hr (□, ▪) at 30°C. The concentrations of \[^3^H\]NMS and \[^3^H\]QNB were 0.131 ± 0.003 nM and 0.022 ± 0.005 nM, respectively, and the corresponding affinities (*K*~D~) were 0.46 ± 0.03 nM and 0.039 ± 0.008 nM. Data from three (3 hr) or two (12 hr) experiments were analyzed simultaneously according to [Equation 2](#equ2){ref-type="disp-formula"}, taken with two terms for \[^3^H\]NMS (*n* = 2) and one term for \[^3^H\]QNB (*n* = 1). The lines depict the best fits of the model, and the parametric values are listed in [Figure 1---source data 2](#SD2-data){ref-type="supplementary-material"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.007](10.7554/eLife.11685.007)10.7554/eLife.11685.008Figure 1---figure supplement 2.Simulated effect of strychnine on the binding of \[^3^H\]NMS according to [Figure 6](#fig6){ref-type="fig"}.Total specific binding of the orthosteric ligand (RL + ARL) at graded concentrations of strychnine was simulated according to [Figure 6](#fig6){ref-type="fig"} ([Equations 13--17](#equ14 equ15 equ16 equ17 equ18){ref-type="disp-formula"}) with the parametric values listed in [Figure 1-source data 3](#SD3-data){ref-type="supplementary-material"}. The concentration of NMS was taken as equal to the dissociation constant (*i.e*., 10 nM). The level of binding was computed for different times after the simultaneous addition of both ligands (**A**), after the addition of NMS to a system pre-equilibrated with strychnine (**B**), and after the addition of strychnine to a system pre-equilibrated with NMS (**C**). The times of incubation were as follows: 5 min (*a*), 20 min (*b*), and sufficient time for the attainment of equilibrium (*c*).**DOI:** [http://dx.doi.org/10.7554/eLife.11685.008](10.7554/eLife.11685.008)

Monomeric M~2~ receptors retain the interaction between ligands at the allosteric and orthosteric sites. The allosteric modulator gallamine slowed the dissociation of \[^3^H\]QNB, and the time-course of the dissociation was mono-exponential under all conditions. The dose-dependence of the decrease in the rate constant was monophasic with a Hill coefficient of 1 ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Gallamine therefore appears to slow the release of \[^3^H\]QNB from monomers via a single allosteric site. In contrast, two or more allosteric sites can be inferred from the bell-shaped behavior of receptors that are predominantly or wholly oligomeric ([@bib28]) ([Figure 1C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

Monomers of the M~2~ receptor equilibrated slowly with \[^3^H\]NMS and either gallamine or the allosteric modulator strychnine when the two ligands were added simultaneously, and incubation for 21 hr was required for the attainment of equilibrium at 30°C. The binding profile upon equilibration was monophasic downward in each case, and the data can be described by a single hyperbolic term (*i.e.*, [Equation 2](#equ2){ref-type="disp-formula"}, *n* = 1) ([Figure 1D and E](#fig1){ref-type="fig"}; [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Gallamine and strychnine therefore appear to modulate the equilibrium binding of \[^3^H\]NMS to monomers via a single allosteric site.

The monophasic nature of effects observed at purified monomers differs from the triphasic effect of gallamine on the binding of \[^3^H\]NMS to M~2~ receptors in other preparations, including membranes and detergent-solubilized extracts from *Sf*9 cells, CHO cells, and porcine atria (*e.g.*, [Figure 1D](#fig1){ref-type="fig"}, broken line) ([@bib28]). Those multiphasic curves and the Hill coefficients of the individual components, taken together, are indicative of at least four interacting allosteric sites, which in turn are suggestive of four interacting receptors within a tetramer or larger oligomer. Similarly, the bell-shaped pattern obtained for strychnine in atrial extracts ([Figure 1E--G](#fig1){ref-type="fig"}) and in membranes from CHO cells ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}, [Figure 1---source data 2](#SD2-data){ref-type="supplementary-material"}) is indicative of at least two allosteric sites and also points to an oligomer.

Allosteric ligands bind in a vestibule to the orthosteric site ([@bib12]), forming a cap that impedes the binding and dissociation of the orthosteric ligand ([Figure 6](#fig6){ref-type="fig"}) ([@bib28]). Interference by one ligand in the binding kinetics of another leads to binding patterns that depend upon the order of mixing in a system that has not attained equilibrium. Such kinetic effects were examined experimentally by varying the sequence in which strychnine and \[^3^H\]NMS were added to the receptor. In one protocol, the two ligands were added simultaneously and incubated with the receptor for 21 hr to obtain the pattern at equilibrium. In another, one ligand was pre-equilibrated with the receptor prior to the addition of the second, and the mixture was incubated for a further 3 hr to obtain the pattern at a time prior to equilibrium.

With receptors in atrial extracts, the effect of strychnine on the binding of \[^3^H\]NMS was bell-shaped under all conditions ([Figure 1E--G](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). With purified monomers, strychnine was strictly inhibitory except when the receptor was pre-equilibrated with \[^3^H\]NMS, when there was no effect ([Figure 1E--G](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). The patterns observed in experiments on monomers are consistent with the patterns observed in simulations performed according to [Figure 6](#fig6){ref-type="fig"} ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 1---source data 3](#SD3-data){ref-type="supplementary-material"}), which describes a mechanism for allosteric capping of the orthosteric site in a monomer.

A FRET-based sensor of allosteric effects {#s2-2}
-----------------------------------------

Allosteric effects that produce multiphasic binding profiles such as those illustrated by the dashed lines in [Figure 1C,D](#fig1){ref-type="fig"} have been attributed to a combination of inter- and intramolecular interactions within oligomers ([@bib28]). For more direct information on those interactions and related conformational changes, we developed a sensor based on FRET between FlAsH and mCherry. FlAsH was incorporated via the hairpin-forming sequence FLNCCPGCCMEP (FCM) ([@bib10]), which was inserted after Val^166^ in the second extracellular loop (ECL2), and mCherry was fused to the amino terminus (*i.e.*, mCh-M~2~-FCM).

A fluorophore at the *N*-terminus of the M~2~ receptor has been shown previously to have no discernible effect on various properties, including transport of the receptor to the plasma membrane, agonist-induced responses, and the binding of muscarinic ligands ([@bib22]). Localization at the plasma membrane also was not affected by the modifications described here, as visualized by fluorescence from either the fused fluorophore or bound FlAsH ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), nor was there any apparent change in the binding properties. The affinity of the receptor for \[^3^H\]NMS was essentially the same, as measured in preparations of membrane-bound and detergent-solubilized mCh-M~2~-FCM from transfected CHO cells ([Equation 3](#equ4){ref-type="disp-formula"}: membranes, log *K* = −9.52 ± 0.10, *N* = 3; extract, log *K* = −8.26 ± 0.22, *N* = 3). The modified receptor also retained the triphasic allosteric effect of gallamine on the binding of \[^3^H\]NMS, as measured in membranes from CHO cells expressing mCh-M~2~-FCM ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}).

Molecular models of the native M~2~ receptor, mCh-M~2~-FCM, and the FlAsH-bound sensor were rendered from the crystal structures of mCherry (2H5Q) ([@bib1]) and the receptor in an active state (4MQS) ([@bib12]). A structure of the sensor showing the positions of FlAsH and mCherry is given in [Figure 2A](#fig2){ref-type="fig"}. Insertion of the FlAsH-reactive sequence in ECL2 created a rigid extended loop ([Figure 2B](#fig2){ref-type="fig"}) without perturbing the conformation of the loop in the region of the adjacent EDGE motif. There was no distortion of the extended loop upon the addition of FlAsH.10.7554/eLife.11685.009Figure 2.FRET-based detection of conformational change at the allosteric site.(**A**) A computed molecular model of the M~2~ receptor (red) fused at the *N*-terminus to mCherry (yellow) and labeled with FlAsH (green) at a tetracysteine motif inserted in ECL2 between Val^166^ and Gly^167^. (**B**) Expanded views of ECL2 with the insert FCM and FlAsH. (**C**) M~2~ receptor bearing mCherry and the FlAsH-reactive insert (mCh-M~2~-FCM) was expressed in CHO cells and treated with FlAsH. Images were collected upon excitation at 498 nm and 0.37 *µ*W. The emission spectrum from a single cell is shown in the figure (**C**). The spectrum was unmixed ([Equation 10](#equ11){ref-type="disp-formula"}) to obtain the contributions of donor (*k*~D~, green) and acceptor (*k*~A~, red) to the fitted sum (black). (**D**) CHO cells expressing mCh-M~2~-FCM or the mCherry-tagged wild-type M~2~ receptor (mCh-M~2~) were treated with FlAsH and excited at 498 nm. The FRET efficiencies (*E*~app~) calculated for individual cells are shown as histograms, and the dashed lines depict the best fits of the Gaussian distribution (dark grey bars, mCh-M~2~-FCM, 31 cells, *μ* = 59.2 ± 1.2, *σ* = 7.7 ± 3.0; light grey bars, mCh-M~2~, 34 cells, *μ* = 0.50 ± 0.35, *σ* = 1.8 ± 0.5. (**E**) mCh-M~2~-FCM was expressed in CHO cells and reacted with FlAsH, and the value of *E*~app~ was measured before and after addition of the inverse agonist NMS (1 *µ*M, *N* = 26), the allosteric modulator gallamine (Gal, 10 mM, *N* = 42), NMS (1 *µ*M) plus gallamine (10 mM, *N* = 18), the agonist carbachol (Car, 1 mM, *N* = 19), and the partial agonist pilocarpine (Pilo, 1 mM, *N* = 19). The ligand-dependent changes in *E*~app~ are plotted in the figure (*i.e.*, ∆*E*~app~ ± S.D.), and the values are listed and compared in [Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}. The mean value of *E*~app~ for cells in the absence of ligand was 60 ± 8% (*N* = 26).**DOI:** [http://dx.doi.org/10.7554/eLife.11685.009](10.7554/eLife.11685.009)10.7554/eLife.11685.010Figure 2---source data 1.*Panel A*--Time-resolved fluorescence and fluorescence anistoropy of eGFP and eGFP-tagged M~2~ receptors.*Panel E--*Levels of significance for ligand-dependent changes in the FRET efficiency of FlAsH-reacted mCh-M~2~-FCM.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.010](10.7554/eLife.11685.010)10.7554/eLife.11685.011Figure 2---figure supplement 1.Expression and localization of fluorophore-tagged M~2~ receptors.CHO cells were transfected with plasmids coding for mCh-M~2~-FCM (**A**), mCh-M~2~(D103A)-FCM (**B**), M~2~-FCM (**C**), eGFP-M~2~ (**D**), mCh-M~2~ (**E**), and eGFP-M~2~-mCh (**F**). Images were recorded on a confocal microscope, as described in Materials and methods, and those shown in the figure were obtained at the middle of the cell in the Z-plane. Cells were labelled with FlAsH and excited at 488 nm to obtain the images in **A--C**. eGFP was excited at 488 nm to obtain the image in **D**, and mCh was excited at 561 nm to obtain the images in **E** and **F**.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.011](10.7554/eLife.11685.011)10.7554/eLife.11685.012Figure 2---figure supplement 2.Modulatory effect of gallamine on the binding of \[^3^H\]NMS to mCh-M~2~-FCM.Membranes were prepared from CHO cells expressing M~2~ receptor bearing mCherry at the *N*-terminus and the FlAsH-reactive sequence FCM in the second extracellular loop. The binding of \[^3^H\]NMS was measured at the concentrations of gallamine (M) shown on the x-axis. Both ligands were added simultaneously, and the reaction mixture was incubated for 16 hr at 25ºC. The line depicts the best fit of Equation 2 to all of the data taken in concert. The values of log *K*~j~ were common to all of the data, and the fitted estimates are as follows: log *K*~1~ = −6.39 ± 0.10, log *K*~2~ = −3.15 ± 0.63, log *K*~3~ = −2.60 ± 0.59. The values of *n*~H(*j*)~ were indistinguishable from 1, either individually or collectively (p≥0.13), and were fixed accordingly. The mean concentration of \[^3^H\]NMS was 3.08 ± 0.05 nM. Points at the left- and right-hand ends of the abscissa (F) depict binding in the absence of unlabeled ligand and in the presence of 3 μM atropine.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.012](10.7554/eLife.11685.012)10.7554/eLife.11685.013Figure 2---figure supplement 3.FRET between eGFP fused at the *N*-terminus and mCherry inserted after Val^166^.CHO cells expressing the eGFP- and mCherry-tagged M~2~ receptor were excited at 473 nm at a power of 0.37 µW. The emission spectrum was recorded from the region of the plasma membrane and analyzed to obtain the apparent FRET efficiency. (**A**) The distribution of FRET efficiencies from 33 cells. The dotted line depicts the best fit of a Gaussian distribution (μ = 9.51, σ = 0.11). (**B**) The mean FRET efficiency (± S.D.) measured in the absence of ligand, in the presence of NMS (1 µM) (9.1 ± 1.6, 20 cells), or in the presence NMS (1 µM) plus gallamine (1 mM) (9.7 ± 1.0, 18 cells)**DOI:** [http://dx.doi.org/10.7554/eLife.11685.013](10.7554/eLife.11685.013)

To examine the mobility of a fluorophore at the amino terminus, eGFP was fused to the wild-type M~2~ receptor (eGFP-M~2~) and to a truncated mutant lacking the first 13 amino acids (eGFP-truncM~2~). This truncation shortened the link between the fluorophore and the first helical domain and was expected to increase the likelihood that the movement of eGFP would approximate that of the fusion protein as a whole. Each tagged receptor was expressed in CHO cells and extracted in digitonin--cholate, and the rotational correlation time (*φ*) of the fused fluorophore was estimated from the fluorescence anisotropy according to [Equations 4--9](#equ5 equ6 equ7 equ8 equ9 equ10){ref-type="disp-formula"}. The full-length receptor was examined with and without ligands, and eGFP alone was taken as a control.

Both the fluorescence ([Equation 6](#equ7){ref-type="disp-formula"}) and the anisotropy ([Equation 9](#equ10){ref-type="disp-formula"}) decayed as a single exponential under all conditions, and the parametric values are listed in [Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}. The value of 18 ns obtained for the correlation time of free eGFP agrees favourably with that of about 20 ns reported previously ([@bib4]) and was sixfold longer than the fluorescence lifetime of 3 ns. In contrast, values of 30--55 ns were obtained for eGFP-truncM~2~, eGFP-M~2~, and the various liganded states of eGFP-M~2~. Such values are at least 12--22-fold longer than the corresponding lifetimes of 2.5--2.6 ns, and the latter are much shorter than the 12-ns measuring window of the fluorescence decay. The rotational correlation times obtained for receptor-bound eGFP therefore are indistinguishable, and the movement of the fluorophore at the *N*-terminus of the receptor appears to be determined primarily by the tumbling of the whole protein, with or without ligands.

Excitation of bound FlAsH at 498 nm gave the observed emission spectrum and unmixed components shown for a typical cell in [Figure 2C](#fig2){ref-type="fig"}. Fluorescence from the acceptor accounted for most of the total signal at 610 nm, and the corresponding peak derived predominantly from FRET. Only 6% of the emission from the acceptor came from direct excitation, and it was accounted for during spectral unmixing. The apparent FRET efficiency of each cell was calculated from the normalized amplitudes of the unmixed spectra ([Equations 10 and 12](#equ11 equ13){ref-type="disp-formula"}), and the efficiencies from all cells gave a distribution centered on 60% with a width of 18% at half-maximal amplitude ([Figure 2D](#fig2){ref-type="fig"}). Controls in which FlAsH was reacted with mCherry-tagged receptors lacking the FCM sequence gave a narrow distribution centered on 0.5% ([Figure 2D](#fig2){ref-type="fig"}), confirming the specificity of the reaction with FlAsH.

The emission spectrum and corresponding FRET efficiency between FlAsH and mCherry was measured for each cell before and after the addition of various ligands. The inverse agonist NMS caused a marked increase in the amplitude of the peak near 610 nm, as illustrated in [Figure 3A](#fig3){ref-type="fig"}. Smaller increases were obtained with the partial agonist pilocarpine, the allosteric modulator gallamine, and the combination of gallamine plus NMS. In contrast, the agonist carbachol caused a decrease. The differences in efficiency at individual cells were averaged over all cells to obtain the mean for each ligand ([Figure 2E](#fig2){ref-type="fig"}, [Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}), which varied from an increase of 20 percentage points with NMS to a decrease of 22 percentage points with carbachol. The partial agonist pilocarpine caused an increase of 7.3 percentage points. These changes indicate that the sensor can distinguish between agonists and an inverse agonist at the orthosteric site. Gallamine caused an increase of 5.0 percentage points and reduced the increase caused by NMS from 22 to 8.0 percentage points, indicating that the sensor detects the effect of the allosteric ligand on NMS.10.7554/eLife.11685.014Figure 3.The nature of high-affinity allosteric interactions.The sensor (mCh-M~2~-FCM) (**A**), a mutant thereof that does not bind NMS \[mCh-M~2~(D103A)-FCM\] (**B**), and the mutant plus the wild-type M~2~ receptor (**C**) were expressed or co-expressed in CHO cells and reacted with FlAsH. The cultures were irradiated before (-- -- ◯ -- --) and after (--- □ ---) the addition of NMS (1 μM), and the emission spectra from individual cells were unmixed to determine the contribution of each component (*k*~D~ and *k*~A~, [Equation 10](#equ11){ref-type="disp-formula"}) and the corresponding FRET efficiency (*E*~app~, [Equation 12](#equ13){ref-type="disp-formula"}). (**D**) Ligand-dependent changes in the FRET efficiency (Δ*E*~app~) were averaged over 18--42 cells transfected as described for panels **A--C**, and the means (± S.D.) are plotted in the figure. The values are listed and compared in [Figure 3---source data 1](#SD5-data){ref-type="supplementary-material"}. The value for mCh-M~2~-FCM is replotted from [Figure 2F](#fig2){ref-type="fig"}. (**E**) A depiction of intermolecular cooperativity within a hetero-oligomer of the M~2~ receptor in which binding is precluded at the orthosteric site of one mutant (M~2~-D103A) and the allosteric site of another (M~2~-ECL~2~+ve). (**F**) CHO cells expressing M~2~-ECL2+ve alone ([○]{.ul}) or together with M~2~-D103A (□) were solubilized in digitonin--cholate, and hetero-oligomers were purified as described in the text. Aliquots of each sample were added to solutions of \[^3^H\]NMS (10 nM) and gallamine at the concentrations shown on the *x*-axis, and binding was measured after incubation of the mixture for 21 hr at 30°C. The solid lines represent the best fits of [Equation 2](#equ2){ref-type="disp-formula"} to the combined data from 3 experiments, and the parametric values are as follows: ○, *n* = 1, log *K* = −3.46 ± 0.16; □, *n* = 3, log *K*~1~ = 6.25 ± 0.16, log *K*~2~ = 4.29 ± 0.37, log *K*~3~ = 3.31 ± 0.29. All values of *n*~H(*j*)~ were indistinguishable 1 and fixed accordingly (p≥0.06). The broken line is the difference between the fitted curves for M~2~-ECL2+ve and the copurified heteromer. \[^3^H\]NMS bound to detergent-solubilized M~2~-ECL2+ve with an affinity of 5.5 nM ([Equation 3](#equ4){ref-type="disp-formula"}, log *K* = −8.26 ± 0.10, *n*~H~ = 1, *N* = 3).**DOI:** [http://dx.doi.org/10.7554/eLife.11685.014](10.7554/eLife.11685.014)10.7554/eLife.11685.015Figure 3---source data 1.*Panel D--*Levels of significance for ligand-dependent changes in the FRET efficiency of FlAsH-reacted mCh-M~2~-FCM and mCh-M~2~(D103A)-FCM**DOI:** [http://dx.doi.org/10.7554/eLife.11685.015](10.7554/eLife.11685.015)10.7554/eLife.11685.016Figure 3---figure supplement 1.Coexpression of the M~2~ receptor and a non-binding sensor.(**A**) CHO cells were cotransfected with the plasmids coding for eGFP-M~2~ and mCh-M~2~(D103A)-FCM. The cells were treated with FlAsh, and those expressing both receptors were identified by the presence of both eGFP and mCherry. (**B**, **C**) The emission was recorded in absence of ligand (**B**) and in the presence of NMS (1 μM) (**C**), and the spectra were unmixed according to [Equation 11](#equ12){ref-type="disp-formula"} to obtain the contribution of each fluorophore. The circles are the measured spectrum, and the solid lines are the best fits of [Equation 11](#equ12){ref-type="disp-formula"}. The dashed lines depict the constituent spectra as follows: eGFP, blue; FlAsH, green; mCherry, red. The FRET efficiency between FlAsH and mCherry was computed from the unmixed contributions according to [Equation 12](#equ13){ref-type="disp-formula"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.016](10.7554/eLife.11685.016)

A receptor bearing eGFP at the *N*-terminus and mCherry rather than FlAsH-FCM after Val^166^ in ECL2 gave a comparatively narrow distribution of FRET efficiencies with a mean of about 10% and a width of about 4% ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}). The effects of NMS and gallamine on FRET were eliminated ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}), suggesting that the insertion of mCherry within ECL2 disrupts the vestibule to the orthosteric site. The distribution of FRET efficiencies was narrower than that obtained with FlAsH and mCherry in the sensor, where the greater width of 40% may arise from differences in the labelling efficiency of FlAsH among different cells.

Intermolecular modulation of FRET {#s2-3}
---------------------------------

The substitution of alanine for aspartic acid at position 103 of the M~2~ receptor removes the counter-ion for positively charged ligands at the orthosteric site ([@bib8]). That mutation has been shown previously to prevent the specific binding of \[^3^H\]NMS or \[^3^H\]QNB to M~2~ receptors in HEK293 membranes at concentrations of the radioligand up to 10 nM ([@bib9]). The same mutation in the sensor prevented the specific binding of \[^3^H\]NMS at a concentration of 1 *µ*M, as measured with mCh-M~2~(D103A)-FCM extracted from transfected CHO cells in digitonin--cholate. It also eliminated the effect of NMS on FRET. There was essentially no change in the emission spectrum at 610 nm ([Figure 3B](#fig3){ref-type="fig"}), in contrast to the increase observed with FlAsH-treated mCh-M~2~-FCM ([Figure 3A](#fig3){ref-type="fig"}); also, the NMS-dependent increase in the mean FRET efficiency was reduced from 21.6 ± 11.2 percentage points in mCh-M~2~-FCM to 0.45 ± 0.55 percentage points in the mutant ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---source data 1](#SD5-data){ref-type="supplementary-material"}).

Sensitivity to NMS was recovered when the binding-deficient mutant was co-expressed with the wild-type M~2~ receptor ([Figure 3C and D](#fig3){ref-type="fig"}), resulting in a ligand-dependent change in the mean FRET efficiency of 9.5 ± 1.8 percentage points ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---source data 1](#SD5-data){ref-type="supplementary-material"}). The recovery indicates that M~2~ receptors occur at least partly as oligomers in which the conformation in the region of the allosteric site of one protomer is affected by a ligand at the orthosteric site of another.

In cells such as that represented in [Figure 3C](#fig3){ref-type="fig"}, co-existence of the wild-type receptor and FlAsH-reacted mCh-M~2~(D103A)-FCM is inferred from the effect of NMS on FRET. To confirm the cellular co-localization of the two proteins, cells were co-transfected with the plasmids for mCh-M~2~(D103A)-FCM and the wild-type receptor fused at the *N*-terminus to eGFP (eGFP-M~2~). Those FlAsH-treated cells displaying three fluorophores, and therefore both proteins, were identified by their spectral properties, and those spectra were unmixed to obtain the individual contribution from each fluorophore ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). NMS increased the FRET efficiency between FlAsH and mCherry by 5.3 ± 0.1 percentage points (*N* = 26) rather than 9.5 percentage points, in a further indication that the conformational change detected by FRET in one protomer derives from the binding of the ligand to another.

Intermolecular modulation of binding {#s2-4}
------------------------------------

The first two inflections of the triphasic binding profile exhibited by gallamine have been attributed to intermolecular modulation via allosteric sites on different protomers of an oligomer ([@bib28]). In a direct test for such interactions, the three negatively charged residues of the [ED]{.ul}G[E]{.ul} motif in ECL2 were replaced by three positively charged residues (*i.e.*, [KR]{.ul}G[K]{.ul}) to obtain a mutant in which the binding of a cationic ligand such as gallamine to the allosteric site is precluded by electrostatic repulsion (M~2~-ECL2+ve). When the mutant was expressed in CHO cells and extracted in digitonin--cholate, the substitution was found to be without effect on the affinity of \[^3^H\]NMS for the orthosteric site ([Equation 3](#equ4){ref-type="disp-formula"}, log *K* = −8.26 ± 0.10, *N* = 3). The triphasic pattern revealed by gallamine at the wild-type receptor was lost, however, and in its place was a single inflection of comparatively low affinity (log *K* = −3.46 ± 0.16) ([Figure 3F](#fig3){ref-type="fig"}).

FLAG-tagged receptors lacking the orthosteric site (FLAG-M~2~(D103A)) then were co-expressed with hexahistidyl-tagged receptors lacking the allosteric site (His~6~-M~2~-ECL2+ve), and purified complexes containing at least one copy of each mutant were obtained by successive passage of detergent-solubilized material on an immuno-affinity column of immobilized anti-FLAG antibody (Santa Cruz Biotechnology) and a chelating resin of Ni^2+^-NTA ([Figure 3E](#fig3){ref-type="fig"}). Binding of \[^3^H\]NMS to the purified heteromer displayed a triphasic dependence on the concentration of gallamine ([Figure 3F](#fig3){ref-type="fig"}), and the apparent affinities calculated in terms of [Equation 2](#equ2){ref-type="disp-formula"} ([Figure 3F](#fig3){ref-type="fig"}, legend) were in good agreement with those reported for the wild-type receptor ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}) ([@bib28]). The magnitude of the inhibitory effect corresponding to the allosteric sites of weakest affinity was much less than that observed with the wild-type receptor (cf. [Figure 1D](#fig1){ref-type="fig"}, broken line). It was diminished further when corrected by subtraction of the single inhibitory component observed with M~2~-ECL2+ve ([Figure 3F](#fig3){ref-type="fig"}, broken line).

Molecular dynamics simulations of the liganded receptor {#s2-5}
-------------------------------------------------------

Allosteric effects were examined in molecular dynamics simulations at the atomic level, starting from the crystal structure of the monomeric M~2~ receptor occupied by the agonist iperoxo (4MQS) ([@bib12]). The ligand and accessory proteins were removed, and conformations of the receptor were sampled from a canonical ensemble accessible within a period of 30 ns. Simulations were performed in the absence of membrane and detergent, and ligands were docked prior to initiating the calculation. Interactions between allosteric and orthosteric ligands ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) were found to be affected by the degree of electrostatic repulsion between their positive charges and the conformational changes induced in one site by a ligand at the other, which together determine the positional stability of each ligand in its respective site.

The effect of electrostatic repulsion was evaluated by two correlates ([Table 1](#tbl1){ref-type="table"}): the distance between the spatial centers of the cationic nitrogen atoms of the two ligands (*e.g*., strychnine and NMS, [Figure 4A](#fig4){ref-type="fig"}; gallamine and QNB, [Figure 4B](#fig4){ref-type="fig"}), and changes in the electrostatic potential of an allosteric ligand upon the addition of an orthosteric ligand. All four allosteric--orthosteric pairs showed a degree of electrostatic repulsion, but steric effects reduced the difference between strychnine and gallamine to less than would be predicted on the basis of charge alone ([Table 1](#tbl1){ref-type="table"}). Gallamine has three cationic groups and therefore experiences greater electrostatic repulsion overall, but each group is surrounded by sterically bulky and electron-rich ethyl groups that diminish the repulsive effect ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Also, the smaller steric load born by the single cationic nitrogen atom of strychnine allows for positioning closer to the orthosteric site.10.7554/eLife.11685.017Table 1.Correlates of electrostatic repulsion between orthosteric and allosteric ligands. The inter-cationic distance was calculated as that between the cationic nitrogen atom of the orthosteric ligand and the closest cationic nitrogen atom of the allosteric ligand. The difference in electrostatic potential was calculated as the increase in electrostatic energy of an allosteric modulator at a receptor with a vacant orthosteric site over that of the same modulator at a receptor with NMS or QNB at the orthosteric site.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.017](10.7554/eLife.11685.017)Allosteric--orthosteric pairStr_R\_NMS*^a^*Str_R\_QNBGal_R\_NMSGal_R\_QNB*^a^*Inter-cationic distance (Å)13.715.716.516.8Difference in electrostatic potential (kcal/mol)0.00850.0630.0960.41[^3]10.7554/eLife.11685.018Figure 4.Intramolecular interactions between orthosteric and allosteric ligands.Models of the liganded receptor were simulated by molecular dynamics as described in Materials and Methods. The region of the ligand-binding sites is shown in the figure, with NMS and strychnine (**A**, **C**) or with QNB and gallamine (**B**, **D**) at the ortho- and allosteric sites, respectively. (**A**, **B**) The electrostatic potential of each ligand is displayed on a molecular surface within 4.5 Å of the constituent atoms (positive potential, blue; negative potential, red). The values and corresponding arrows are the distances between the centers of the cationic ammonium groups of the orthosteric and allosteric ligands. The closest such group is shown in the case of gallamine. (**C**, **D**) The bound ligands are shown together with residues involved in receptor-ligand interactions.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.018](10.7554/eLife.11685.018)10.7554/eLife.11685.019Figure 4---figure supplement 1.Chemical structures of allosteric and orthosteric ligands to the M~2~ muscarinic receptor.The ligands shown are: NMS, *N*-methylscopolamine; QNB, quinuclidinylbenzilate; Str, strychnine; and Gal, gallamine. Different liganded states of the receptor are identified as X_R\_Y, where X and Y are the allosteric and orthosteric ligands, respectively. Occupancy is represented as O for a vacant site or as Str, Gal, NMS, or QNB for a ligand-occupied site.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.019](10.7554/eLife.11685.019)

A network of interactions serves as a conformational link between the allosteric and orthosteric sites. Three tyrosine residues form a hydrogen-bonded aromatic cap over the orthosteric site (*i.e.*, Tyr^104^, Tyr^403^, and Tyr^426^) ([@bib12]). Between the cap and the allosteric site is a tryptophan residue that interacts with the cationic nitrogen atom of the allosteric ligand (*i.e.*, Trp^422^). Tyrosine 426 within the aromatic cap and Trp^422^ are linked via the peptide backbone of helix 7 ([Figure 5](#fig5){ref-type="fig"}). In the absence of an orthosteric ligand, the orientation of Trp^422^ is unfavorable for the interaction with a cationic allosteric ligand ([Figure 5A](#fig5){ref-type="fig"}).10.7554/eLife.11685.020Figure 5.Effects of orthosteric and allsteric ligands on the aromatic cap and Trp^422^.(**A**) The three residues of the aromatic cap (*i.e.*, Tyr^104^, Tyr^403^, and Tyr^426^) and Trp^422^ are shown in an overlay of the results of three simulations: a vacant receptor (yellow), a QNB-bound receptor (green), and a receptor occupied by both QNB and gallamine (pink). The ligands are not shown. (**B**) The receptor with QNB at the orthosteric site. (**C**) The receptor with QNB at the orthosteric site and gallamine at the allosteric site. Here and elsewhere, different liganded states of the receptor are identified as X_R\_Y, where X and Y are the allosteric and orthosteric ligands, respectively. Occupancy is represented as O for a vacant site or as Str (strychnine), Gal (gallamine), NMS, or QNB for a ligand-occupied site.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.020](10.7554/eLife.11685.020)10.7554/eLife.11685.021Figure 5---source data 1.Figure 5--figure supplement 2--Distance between the α-carbon atoms of Tyr^177^ and Asn^419^ in crystal structures of the M~2~ receptor**DOI:** [http://dx.doi.org/10.7554/eLife.11685.021](10.7554/eLife.11685.021)10.7554/eLife.11685.022Figure 5---source data 2.Figure 5--figure supplement 3--Mean distances (Å) between the *α*-carbon atoms of Tyr^177^ and Asn^419^ in the M~2~ receptor with different combinations of allosteric and orthosteric ligands**DOI:** [http://dx.doi.org/10.7554/eLife.11685.022](10.7554/eLife.11685.022)10.7554/eLife.11685.023Figure 5---figure supplement 1.Orientation of ligands at the orthosteric site.Strychnine adopts a similar pose at the vacant receptor and in the presence of either NMS (**A**) or QNB at the orthosteric site. The position of gallamine at a vacant receptor (**B**) is consistent throughout the simulation. At a QNB-bound receptor (**C**), gallamine is pushed outward, and its orientation is more variable. The orthosteric ligands are not shown in (**A**) and (**C**).**DOI:** [http://dx.doi.org/10.7554/eLife.11685.023](10.7554/eLife.11685.023)10.7554/eLife.11685.024Figure 5---figure supplement 2.Width of the vestibule to the orthosteric site.Changes in the distance between the α-carbon atoms of Tyr^177^ and Asn^419^ were taken as a measure of the effect of an orthosteric ligand on the conformation of the allosteric site. The structures of the receptor with QNB (3UON, white) and iperoxo (4MQS, pink) at the orthosteric site are superimposed, and the allosteric site is shown as occupied by strychnine. The perspective is toward the extracellular surface of the receptor.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.024](10.7554/eLife.11685.024)10.7554/eLife.11685.025Figure 5---figure supplement 3.Distribution of distances between the α-carbon atoms of Tyr^177^ and Asn^419^.The distances from all frames of the molecular dynamics simulations over the production period of 30 ns are shown in the figure for a receptor with NMS (**A**) or QNB (**B**) at the orthosteric site. In each case, the allosteric site was vacant (red), occupied by strychnine (green), or occupied by gallamine (blue).**DOI:** [http://dx.doi.org/10.7554/eLife.11685.025](10.7554/eLife.11685.025)

Binding of NMS or QNB at the orthosteric site reduces the mobility of the residues of the aromatic cap (*e.g.*, [Figure 5A and B](#fig5){ref-type="fig"}) and orients Trp^422^ to interact with the cationic group of an allosteric ligand. The effect is greater with QNB than with NMS owing to the additional phenyl ring of QNB. Binding of an allosteric ligand draws the aromatic cap outward, leading to destabilization of the orthosteric ligand and greater flexibility in the region of the orthosteric site (*e.g.*, [Figure 5A and C](#fig5){ref-type="fig"}). The effect is greater with gallamine than with strychnine, owing to the greater size and charge of gallamine, and it is suggestive of a reduction in the affinity of the receptor for orthosteric ligands.

Gallamine and strychnine affect the conformation of the receptor through interactions between the cationic ammonium group of each allosteric ligand and the side-chains of Trp^422^ and Tyr^177^. Gallamine also affects the receptor through *π*-cation interactions with Tyr^80^ and Tyr^83^ and through electrostatic interactions with Glu^172^ of the EDGE motif. The overall conformational effect of these interactions was tracked by measuring the distance between the *α*-carbon atoms of Tyr^177^ and Asn^419^. That distance is a measure of the width of the vestibule (*e.g.*, [Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}), and it differs among crystal structures of the M~2~ receptor in different liganded states ([Figure 5---source data 1](#SD6-data){ref-type="supplementary-material"}): namely, with QNB in the orthosteric site (3UON) ([@bib9]), with iperoxo in the orthosteric site (4MQS), and with iperoxo in the orthosteric site and LY2119620 in the allosteric site (4MQT) ([@bib12]).

The width of the vestibule in simulations with NMS or QNB at the orthosteric site was distributed as shown in [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}. The allosteric site was vacant (*e.g.*, O_R\_NMS) or occupied by strychnine or gallamine (*e.g.*, Str_R\_NMS or Gal_R\_NMS). The mean distances obtained for all nine liganded and unliganded states are listed in [Figure 5---source data 2](#SD7-data){ref-type="supplementary-material"}. When the allosteric site is vacant or occupied by strychnine, the vestibule is wider with QNB than with NMS at the orthosteric site. The greater width is due to the additional phenyl ring of QNB, which disrupts the positions of Tyr^403^, Trp^422^, and Asn^419^. The vestibule is narrowest with strychnine and NMS. Other combinations of ligands have little or no effect owing to the bulk of QNB, the charge on gallamine, or both.

Destabilisation of the aromatic cap plus the electrostatic repulsion that exists with all positively charged allosteric--orthosteric pairs seems likely to prevent the simultaneous binding of both ligands to a monomeric receptor. The least disruptive effects of one ligand on the binding of another occurred with NMS and strychnine owing, in part, to conformational flexibility afforded by one ligand at the site of the other. The most disruptive effects occurred with QNB and gallamine owing to interactions involving the second phenyl ring of the former and the additional cationic centers of the latter ([Figure 4C and D](#fig4){ref-type="fig"}).

Discussion {#s3}
==========

Allostery at the M~2~ muscarinic receptor generally has been understood in terms of interactions within a monomer ([@bib2]), but that view disregards the tendency of GPCRs to form oligomers ([@bib18]). Moreover, the oligomeric nature of the M~2~ receptor is evident in the multiphasic effects of allosteric ligands on the dissociation rate of orthosteric antagonists and their binding at equilibrium ([@bib28]) (*e.g.*, [Figure 1](#fig1){ref-type="fig"}). Such effects appear to involve at least four allosteric sites in a mix of intra- and intermolecular heterotropic interactions within a complex of receptors that is tetrameric or larger ([@bib28]).

We show here that all such complexity is lost when the M~2~ receptor is purified as a monomer ([Figure 1](#fig1){ref-type="fig"}). Gallamine and strychnine were strictly inhibitory in their effect on the binding of \[^3^H\]NMS and \[^3^H\]QNB, and the rate of dissociation of \[^3^H\]QNB was decreased at all concentrations of gallamine. In each case, the dose-dependence was monophasic with a Hill coefficient of 1. Ligands therefore bind to monomers in the manner expected for a protein with one allosteric site and one orthosteric site, in contrast to the behavior of M~2~ receptors in myocardial membranes and unprocessed solubilized preparations.

With either gallamine or strychnine, the potency defined by the single phase observed with monomers is similar to that defined by the weakest of the two or three components of the multiphasic curves observed with oligomers. It follows that effects associated with allosteric sites of higher affinity are a property of oligomers and derive from intermolecular interactions among the constituent protomers. They include the positive effect of gallamine on the rate of dissociation of \[^3^H\]QNB ([Figure 1C](#fig1){ref-type="fig"}) and varied effects on the binding of \[^3^H\]NMS at equilibrium: namely, negative cooperativity at sites of high affinity for gallamine ([Figure 1D](#fig1){ref-type="fig"}; log *K*~1~ = −5.69, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}), apparent positive cooperativity at sites of intermediate affinity for gallamine ([Figure 1D](#fig1){ref-type="fig"}; log *K*~2~ = −4.59, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}), and positive cooperativity at sites of high affinity for strychnine ([Figure 1E--G](#fig1){ref-type="fig"}).

In the case of gallamine, two further lines of evidence from CHO cells confirm the existence of heterotropic interactions between neighboring protomers and the relationship between those interactions and the allosteric sites of higher affinity. First, mutants lacking either the allosteric site or the orthosteric site were copurified from cotransfected cells to obtain a heteromer that lacks the capacity for intramolecular interactions. The purified complex retained the sites of high and intermediate affinity for gallamine that are seen in native preparations of the wild-type receptor but not the site of low affinity ([Figure 3E,F](#fig3){ref-type="fig"}); whereas the former are associated with oligomers, only the latter is observed in monomers. Second, the orthosteric site was eliminated in an M~2~ receptor bearing mCherry at the *N*-terminus and FlAsH in ECL2, which together serve as a FRET-based sensor of conformation at the allosteric site ([Figures 2A](#fig2){ref-type="fig"}). The FRET efficiency of the binding-deficient mutant was affected by NMS only when the mutant was co-expressed with the wild-type receptor ([Figure 3D](#fig3){ref-type="fig"}).

Three lines of evidence indicate that the FRET-based sensor reports primarily on changes at the allosteric site. A comparison of the fluorescence anisotropies measured for eGFP fused to the *N-*terminus of the M~2~ receptor suggests that the region of the fusion is comparatively rigid and unaffected by orthosteric ligands. In contrast, the FRET efficiency of the sensor expressed alone in CHO cells was increased or decreased by orthosteric ligands in a manner that tracked the pharmacological identity of the ligand as an agonist, a partial agonist, or an inverse agonist ([Figure 2F](#fig2){ref-type="fig"}). Ligand-dependent changes in FRET between FlAsH and mCherry therefore appear to result from changes in the position of ECL2-bound FlAsH. Finally, NMS increased the FRET efficiency by 20 percentage points. Such a change is consistent with the predictions of molecular dynamics simulations for the effect of NMS on the width of the vestibule to the orthosteric site ([Figure 5---source data 1](#SD6-data){ref-type="supplementary-material"}) ([@bib5]).

Allosteric and orthosteric ligands may interact via steric hindrance, conformational changes, or electrostatic effects. In the structure computed for a monomeric M~2~ receptor, the interaction between gallamine or strychnine on the one hand and NMS or QNB on the other is dominated by electrostatic repulsion ([Figure 4](#fig4){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). That explains why gallamine and strychnine were inhibitory in their effect on the binding of \[^3^H\]NMS to purified monomers ([Figure 1B and C](#fig1){ref-type="fig"}), and it suggests a molecular basis for the weak affinities of both ligands in those assays. It also suggests that electrostatic repulsion dominates intramolecular cooperativity between allosteric and orthosteric ligands within the constituent protomers of an oligomer.

The molecular dynamics simulations place each allosteric ligand at the extracellular surface, where it caps the vestibule to the orthosteric site and sterically hinders passage of the orthosteric antagonist ([Figure 4](#fig4){ref-type="fig"}). This arrangement is consistent with crystallographic data on the location of a positive allosteric modulator, LY2119620 ([@bib12]), and with the kinetics of allosteric modulation. A kinetically defined model that describes capping in a monomeric receptor ([Figure 6](#fig6){ref-type="fig"}) predicts that the rate at which the system equilibrates will depend upon the order in which the ligands are added to the receptor ([Figure 1E--G](#fig1){ref-type="fig"}). The predicted effects were observed experimentally with purified monomers of the M~2~ receptor, in that equilibration was slowest when \[^3^H\]NMS preceded strychnine ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}).10.7554/eLife.11685.026Figure 6.A receptor (R) binds an orthosteric ligand (L) and an allosteric ligand (A) to form a ternary complex (ARL).Each ligand can bind separately to form AR or RL, but the ternary complex is accessible only via RL. The orthosteric site of the M~2~ receptor is located within the cluster of helical domains, with access via a vestibule that forms the allosteric site. Occupancy of the latter by an allosteric ligand precludes association and dissociation of the orthosteric ligand. The parameters *k*~−L~ and *k*~+L~ are the first- and second-order rate constants for the binding of L to R; similarly, *k*~−A~ and *k*~+A~ are the first- and second-order rate constants for the binding of A to R. The parameters *k*~−AL~ and *k*~+AL~ are the rate constants for the binding of A to RL.**DOI:** [http://dx.doi.org/10.7554/eLife.11685.026](10.7554/eLife.11685.026)

Allosteric effects in monomers are monophasic, necessarily intramolecular, exclusively negative, and of comparatively low affinity. Those in oligomers may be positive or negative and generally reveal two or more affinities, the weakest of which corresponds to that in monomers. The versatility of oligomers is a consequence of additional mechanistic pathways made possible by intermolecular interactions, which avoid the electrostatic repulsion that dominates intramolecular interactions and enforces negative cooperativity within monomers. Such intermolecular effects presumably are mediated by ligand-sensitive conformational changes transmitted from one protomer of receptor to another.

Although the details of allosteric modulation cannot be determined through simulations based solely on a monomer, some insight into the effects observed with different ligand-pairs may be gained by monitoring the residues that form an aromatic cap over the orthosteric site (*i.e.*, Tyrosines 104, 403, and 426). Positive allosteric modulation by strychnine ([Figure 1E](#fig1){ref-type="fig"}), negative modulation by gallamine at sites of high affinity, and apparent positive modulation by gallamine at sites of intermediate affinity ([Figure 1D](#fig1){ref-type="fig"}) occurred only with NMS as the radioligand. It appears, however, that the positive modulatory effects of strychnine and gallamine are different in kind. Whereas strychnine caused a net increase in the binding of \[^3^H\]NMS, gallamine never raised the level of binding above that in its absence.

The effect of strychnine is a clear example of positive cooperativity, but that of gallamine appears to be an attenuation of negative cooperativity. Strychnine and NMS therefore were the only ligand-pair to display positive cooperativity that was self-evident and unambiguous. They also are the ligand-pair that caused minimal disruption of the aromatic cap in molecular dynamics simulations, and positive cooperativity may be a consequence of attendant conformational flexibility in that region of the receptor. The least flexibility was observed with QNB and gallamine, which engaged only in negative cooperativity.

A similar pattern is seen in the distance between the *α*-carbon atoms of Tyr^177^ and Asn^419^, which is a measure of the width of the vestibule that accommodates the allosteric ligand. Decreases in the width from that in the vacant receptor (11.4 Å) were observed only with NMS at the orthosteric site of an otherwise vacant receptor (10.9 Å) and only with strychnine at the allosteric site of a NMS-liganded receptor (10.1 Å). There was little effect of QNB alone or of other ligand-pairs.

Direct evidence for interactions between the protomers of an oligomer has been obtained by precluding intramolecular effects in studies involving the FRET-based sensor and the binding of \[^3^H\]NMS, and molecular dynamics simulations have provided some insight into the underlying conformational effects. Taken together, the results suggest that intermolecular interactions are associated with narrowing of the vestibule and conformational flexibility around the aromatic cap. Such an arrangement would allow an allosteric ligand to bind with high affinity to protomers with a vacant orthosteric site and thereby to increase the binding of an orthosteric ligand to linked protomers with a vacant allosteric site.

The role of oligomers formed by GPCRs of Family 1A is debated, in part because oligomers are not seen to possess a unique or obligatory functionality. Both monomers and oligomers can activate G proteins, and both display allosteric communication between agonists at the receptor and guanylyl nucleotides at the G protein ([@bib27]). In the case of the M~2~ muscarinic receptor, however, the two forms mediate those effects by different mechanisms. Only oligomers mimic the binding patterns observed in native membranes ([@bib27]). We show here that oligomers of the M~2~ receptor also are responsible for the high-affinity binding of allosteric ligands and for positive allosteric modulation. Whereas both effects are observed routinely with M~2~ receptors in natural membranes, neither is expected or observed with monomers. These observations illustrate the cooperative capability of oligomers formed by GPCRs, and they add to the complexity that must be accommodated in a mechanistic understanding of events at the level of the receptor.

Materials and methods {#s4}
=====================

Construction of plasmids {#s4-1}
------------------------

Substitutions, insertions, and deletions of bases were performed by site-directed mutagenesis (Quick-Change, Agilent Technologies). PAGE-purified primers were obtained from Integrated DNA Technologies (IDT). Constructs were prepared in pcDNA3.1 for expression in CHO cells and in Bac-N-Blue (Life Technologies) for expression in *Sf*9 cells. The human M~2~ muscarinic receptor was used throughout, and all sequences were confirmed by DNA sequencing (Centre for Applied Genomics, Hospital for Sick Children, Toronto).

### Fluorophore-tagged variants of the M~2~ receptor {#s4-1-1}

The receptor was fused at the *N*-terminus to eGFP (eGFP-M~2~) or mCherry (mCh-M~2~). To obtain a FRET-based sensor with fluorescein arsenical hairpin binder (FlAsH) as the donor, the second extracellular loop (ECL2) of mCh-M~2~ was modified by insertion of the FlAsH-reactive sequence MLMCCPGCCMEP (FCM) between Val^166^ and Gly^167^(mCh-M~2~-FCM). Similarly, mCherry was inserted between Val^166^ and Gly^167^ in eGFP-M~2~. To assess the rotational motion of a fluorophore at the *N*-terminus, eGFP was fused to the full-length receptor (eGFP-M~2~) and to a truncated mutant lacking the first 13 amino acids (eGFP-truncM~2~) (forward primer, 5\'-GGCATGGACGAGCTGTACAAGAATAGTCCTTATAAGAC-3\'). Further details are provided in Appendix 1 

### Binding-defective mutants of the M~2~ receptor {#s4-1-2}

To preclude binding to the allosteric site, negatively charged residues in the EDGE sequence at positions 172--175 of ECL2 were replaced by positively charged residues (*i.e.*, Lys^172^Arg^173^Gly^174^Lys^175^). To preclude binding to the orthosteric site, aspartic acid at position 103 was replaced by alanine in the wild-time receptor \[M~2~(D103A)\] and the sensor \[mCh-M~2~(D103A)-FCM\]. Further details are provided in Appendix 1.

Expression, extraction, and purification of the M~2~ receptor {#s4-2}
-------------------------------------------------------------

### *Sf*9 cells {#s4-2-1}

Human M~2~ muscarinic receptor bearing the c-Myc or FLAG epitope at the *N*-terminus was expressed in *Sf*9 cells as described previously ([@bib27]; [@bib28]) and in Appendix 1. The cells were harvested and solubilized in digitonin--cholate (0.86% digitonin, Wako Chemicals USA; 0.17% cholate, Sigma-Aldrich), and aliquots of the extract were removed for electrophoresis and binding assays. The receptor was purified in predominantly monomeric form by successive passage on DEAE-Sepharose, ABT-Sepharose, and hydroxyapatite. The final concentrations of digitonin and cholate were 0.1% and 0.02%, respectively. Purified receptor was stored at −75°C. Further details regarding the purification and the nature of the purified receptor have been described previously ([@bib27]).

### CHO cells {#s4-2-2}

Chinese Hamster Ovary (CHO) cells stably expressing the wild-type human M~2~ receptor were grown and processed as described previously ([@bib27]; [@bib28]). Cells for transient transfections were grown and processed as described in Appendix 1.

To obtain membranes for binding assays, thawed cells containing wild-type M~2~ receptor or mCh-M~2~-FCM were homogenized and processed as described previously ([@bib27]; [@bib28]). To obtain extracts for measurements of binding or fluorescence anisotropy, thawed cells containing mCh-M~2~-FCM, M~2~-ECL2+ve, M~2~-ECL2+ve plus M~2~(D103A), eGFP-M~2~, or eGFP-truncM~2~ were washed in buffer A \[20 mM HEPES, 20 mM NaCl, 1 mM EDTA, 0.1 mM PMSF, Complete Protease Inhibitor Cocktail tablets (Roche, 1 tablet/50 mL), adjusted to pH 7.40 with NaOH\] and centrifuged for 10 min at 3,000 × *g* and 4°C. The washed cells were resuspended in buffer A, and the mixture was homogenized with three bursts of a Brinkman Polytron (setting 6, 10 s). An aliquot of 100 μL was removed for the determination of total protein. The homogenate then was centrifuged for 30 min at 45,000 × *g* and 4°C, and the pellet was resuspended in buffer A (5.5 g of protein per L) with three bursts of the Polytron (setting 6, 10 s). Solubilization was initiated by the addition of digitonin and sodium cholate to final concentrations of 0.86% and 0.17%, respectively, and the mixture was agitated on a rocking platform for 15 min at room temperature. The sample then was diluted 1:1 in buffer A and centrifuged for 45 min at 45,000 × *g* and 4°C. The supernatant fraction was concentrated (Amicon Ultra-4, 30 kDa, Millipore) and divided into aliquots that were stored at −75°C ([@bib27]; [@bib28]). Such extracts from cells expressing mCh-M~2~-FCM or M~2~-ECL2+ve were characterized for the binding of \[^3^H\]NMS at graded concentrations of the radioligand.

To obtain purified oligomers containing both FLAG-tagged M~2~(D103A) and His~6~-tagged M~2~-ECL2+ve, the solubilized receptor was applied successively to columns of Ni^2+^-nitriloacetic acid (NTA)-agarose (Qiagen) and anti-FLAG Sepharose (Sigma-Aldrich). The columns were pre-equilibrated with buffer A supplemented with digitonin (0.1%) and cholate (0.04%), and the receptor was eluted with the same buffer containing imidazole (150 mM) (Sigma-Aldrich) or FLAG peptide (100 μg/mL) (Sigma-Aldrich), respectively.

### Porcine atria {#s4-2-3}

The M~2~ receptor is the predominant muscarinic subtype in porcine atria ([@bib32]). It was extracted from sarcolemmal membranes according to a two-step procedure in which the membranes were resuspended in buffer B (20 mM imidazole, 1 mM EDTA, 0.1 mM PMSF, 0.02% NaN~3~, adjusted to pH 7.60 with HCl) supplemented with digitonin (0.36%) and cholate (0.08%) (5.5 g of total protein per L), recovered by centrifugation, and resuspended in buffer B supplemented with digitonin (0.8%) and cholate (0.08%). The soluble fraction from the second resuspension, which contained the M~2~ receptor, was stored at −70°C until required for binding assays. Further details have been described previously ([@bib28]) and are summarized in Appendix 1.

Cross-linking, immunoprecipitation, and electrophoresis {#s4-3}
-------------------------------------------------------

### Cross-linking {#s4-3-1}

A solution of the cross-linker *bis*(sulfosuccinimidyl)suberate (BS^3^, Pierce) in deionized water (20 mM) was added to an aliquot of the receptor to yield a final reagent concentration of 2 mM. The mixture was incubated for 30 min at 24°C, and the reaction was terminated by the addition of Tris-HCl (1 M, pH 8.00) to a final concentration of 20 mM. After further incubation for 15 min at 24°C, the sample was stored on ice prior to electrophoresis. Controls lacking BS^3^ were prepared in parallel under otherwise identical conditions.

### Co-immunoprecipitation {#s4-3-2}

An aliquot of the extract (500 μL) from *Sf*9 cells co-expressing the FLAG- and c-Myc-tagged receptors was supplemented with a 50% slurry (20 *µ*L) of agarose-conjugated anti-FLAG anti-body (Santa Cruz Biotechnology, Inc.). The mixture was shaken overnight at 4°C, and immunoadsorbed receptor was collected by centrifugation. The precipitated beads then were washed 4 times with 3 mL of buffer C (20 mM HEPES, 1 mM EDTA, 0.1 mM PMSF, adjusted to pH 7.40 with NaOH) supplemented with digitonin (1%) and cholate (0.001%), and the entire precipitate was applied to the polyacrylamide gel. Following electrophoresis and transfer, the nitrocellulose membrane (Bio-Rad, 0.45 *µ*m) was blotted with anti-c-Myc antibody (Santa Cruz Biotechnology, Inc.) as described previously ([@bib14]).

### Electrophoresis and western blotting {#s4-3-3}

Details regarding these procedures are described Appendix 1.

Labeling of the M~2~ receptor with FlAsH in live cells {#s4-4}
------------------------------------------------------

TC-FlAsH was obtained as a kit from Molecular Probes (Invitrogen), and labeling was carried out under reduced light according to a procedure adapted from the manufacturer's instructions ([@bib10]). Transfected CHO cells growing at 50--75% confluency were washed twice with PBS, and the medium was changed to Opti-MEM reduced serum medium (Life Technologies, Inc.). After further incubation of the cells for 1 hr at 37°C, the medium was removed and replaced by a freshly prepared labeling solution of FlAsH in reduced serum medium (2.5 μM, 1 mL per dish). The culture was incubated for 20 min at 37°C in 5% CO~2~; the labeling solution then was removed, and the cells were washed twice in a buffer containing 500 *µ*M BAL (Life Technologies, Inc.). During the second wash, the BAL buffer was left for 5 min at 37°C prior to its removal. Washed cells were prepared for imaging by the addition of DMEM (2 mL) supplemented with 50 mM HEPES at pH 7.40 (Gibco Life Technologies, Inc.).

Binding assays {#s4-5}
--------------

*N*-\[^3^H\]Methylscopolamine (\[^3^H\]NMS, 87 Ci/mmol) and (−)-\[^3^H\]quinuclidinylbenzilate (\[^3^H\]QNB, 42 Ci/mmol) were purchased from PerkinElmer as a solution in ethanol, which was removed by evaporation prior to use. Strychnine, gallamine, carbachol, pilocarpine, and unlabeled NMS and QNB were purchased from Sigma-Aldrich. All other reagents were from the sources described previously ([@bib28]).

Binding was measured at pH 7.40 in buffer C or buffer D (Dulbecco's phosphate-buffered saline, Sigma-Aldrich D5652, supplemented with 1 mM CaCl~2~ and 1 mM MgCl~2~). In the case of detergent-solubilized preparations, buffer C was supplemented with digitonin (1%) and cholate (0.02%). The separation of free and bound radioligand was achieved by chromatography on Sephadex G-50 Fine in the case of detergent-solubilized receptor and by filtration on fiberglass filters or microcentrifugation in the case of membrane-bound receptor. Further details have been described previously ([@bib28]).

The net dissociation of \[^3^H\]QNB over time was analyzed in terms of a single exponential according to [Equation 1](#equ1){ref-type="disp-formula"}, in which *k*~obsd~ is the rate constant; *B*~obsd~ represents total binding of the radioligand at time t, and *B*~t=0~ and *B*~t→∞~ are the initial and asymptotic levels of binding, respectively.$$B_{obsd} = (B_{t = 0} - B_{t\rightarrow\infty})e^{- k_{obsd}t} + B_{t\rightarrow\infty}$$

Time-courses at one or more concentrations of gallamine were accompanied in the same experiment by a control lacking the allosteric ligand. The data from all traces were analyzed in concert with a single value of *B*~t→∞~ and separate values of *k*~obsd~ and *B*~t=0~. The constraint on *B*~t→∞~ was without appreciable effect on the sum of squares (p\>0.05). The value of *k*~obsd~ measured in the absence of gallamine was designated *k*~0~ and used to normalize each value measured in the presence of gallamine (*i.e., k*~obsd~/*k*~0~).

Dose-dependent effects of an allosteric modulator (A) on the normalized rate of dissociation of the radioligand (*k*~obsd~/*k*~0~) or on the level of total binding at a specified time (*B*~obsd~) were analyzed empirically in terms of [Equation 2](#equ2){ref-type="disp-formula"}.$$Y_{obsd} = Y_{{\lbrack A\rbrack}\rightarrow\infty} + \left( Y_{{\lbrack A\rbrack} = 0} - Y_{{\lbrack A\rbrack}\rightarrow\infty} \right)\sum\limits_{j = 1}^{n}\frac{F_{j}K_{j}^{n_{H(j)}}}{\lbrack A\rbrack_{t}^{n_{H(j)}}K_{j}^{n_{H(j)}}}$$$$\sum_{j = 1}^{n}F_{j} = 1$$

Estimates of binding at graded concentrations of \[^3^H\]NMS were analyzed in terms of [Equation 3](#equ4){ref-type="disp-formula"}.$$B_{obsd} = B_{max}\frac{\left( \lbrack P\rbrack_{t} - B_{sp} \right)^{n_{H}}}{K^{n_{H}} + \left( {\lbrack P\rbrack_{t}} - B_{sp} \right)^{n_{H}}} + {NS}\left( {\lbrack P\rbrack_{t}} - B_{sp} \right)$$

The parameter *B*~max~ represents the maximal specific binding of the radioligand (P), and *B*~obsd~ and *B*~sp~ represent total and specific binding, respectively, at the total concentration \[P\]~t~; *n*~H~ is the Hill coefficient, and *K* is the concentration of unbound \[^3^H\]NMS that corresponds to half-maximal binding. NS is the fraction of unbound radioligand that appears as nonspecific binding. Fitted estimates of the Hill coefficient ranged from 0.93 to 1.03 and were indistinguishable from 1 (p\>0.05).

Analyses in terms of [Equations 1--3](#equ1 equ2 equ4){ref-type="disp-formula"} typically were performed on data from replicate experiments, which were taken in concert to obtain single fitted values of parameters that are expected to be invariant (*i.e., k*~obsd~, *K, n*~H~). In figures that show the results of such analyses, data from individual experiments have been presented with reference to a single fitted curve. To obtain the values plotted on the *y*-axis, measured estimates of *B*~obsd~ or *Y*~obsd~ were adjusted according to the equation $Y^{\prime} = Y\lbrack f(x_{i},\overline{\textbf{a}},\textbf{b})/f(x_{i},\textbf{a},\textbf{b})\rbrack$ ([@bib19]). The function *f* represents the fitted equation, and *x~i~* represents the independent variable at point *i*. The vectors **a** and **b** represent fitted parameters that were estimated separately for each experiment (**a**) or as a single value common to all experiments (**b**); $\mathbf{\overline{a}}$ is the corresponding vector in which parametric values that differed among different experiments have been replaced by the means. Individual values of $Y'$ at the same *x~i~* were averaged to obtain the mean and standard error plotted in the figure. Details regarding the optimization of parameters and statistical procedures are described in Appendix 1.

Fluorescence, microscopy, and image-analysis {#s4-6}
--------------------------------------------

The rotational flexibility of eGFP fused to the *N*-termini of the wild-type M~2~ receptor (eGFP-M~2~) and a truncated mutant (eGFP-truncM~2~) was measured by time-resolved fluorescence anisotropy of single molecules in a locally constructed instrument. Each fusion protein was expressed in CHO cells and solubilized at a concentration of 3--10 nM in buffer C supplemented with detergent (0.8% digitonin, 0.04% sodium cholate). Aliquots of the extract were applied to a coverslip and excited at 480 nm with an excitation beam obtained by frequency-doubling the output of a femtosecond laser (Tsunami HP, Spectra Physics, Santa Clara, CA, USA).

The emission from a confocal volume 5 *µ*m above the surface was passed through a Plan-Apochromat oil-immersion objective (100×, Carl Zeiss, Canada) and projected onto an avalanche photodiode (APD). The emission was divided by means of a polarization cube into two beams with orthogonal polarizations and collected on two different detectors (PDM-5CTC, MPD, Milano, Italy). Photon arrival times were recorded at 4 ps resolution using a multichannel counter (PicoHarp300, PicoQuant, Germany).

The fluorescence signals from the two detectors were fit globally in M[atlab]{.smallcaps} using custom-written software and a Levenberg-Marquardt algorithm with iterative re-convolution. Repetitive excitation and the color off-set (*s*) between measurements of the instrument response function (IRF) and the fluorescence were accounted for according to [Equations 4 and 5](#equ5 equ6){ref-type="disp-formula"}, in which *d~par~* and *d~perp ~*represent the parallel and perpendicular decays before convolution.$$D_{par} = IRF_{par},s \otimes d_{par}$$$$D_{perp} = IRF_{perp},s \otimes d_{perp}$$

The fluorescence signal in each plane was summed to obtain the total fluorescence at time t (*F(*t)), and the lifetime was obtained according to [Equation 6](#equ7){ref-type="disp-formula"}.$$F\left( t \right) = \frac{A}{1 - exp\left( - \frac{T}{\tau} \right)}exp\left( - \frac{t}{\tau} \right)$$

The parameter *A* in [Equation 6](#equ7){ref-type="disp-formula"} is the amplitude, and *T* is the repetition time of the laser (*i.e*., 12.5 ns); t is the time bin, and *τ* is the decay constant. Corrections for collecting the fluorescence emission in the parallel and perpendicular planes through a high numerical-aperture lens were performed according to [Equations 7 and 8](#equ8 equ9){ref-type="disp-formula"}.$$d_{perp} = \left( \frac{1}{3} \right)F\left( t \right)\left( 1 + \left( 1 - 3k_{2} \right)r(t) \right)$$$$d_{par} = G\left( \frac{1}{3} \right)F\left( t \right)\left( 1 + \left( 2 - 3k_{1} \right)r{(t)} \right)$$

The correction factors *k*~1~ and *k*~2~ have values of 0.33 and 0.065, respectively. The correction factor G corrects for the difference in the sensitivity of detection between the two channels and was taken as 1.061, as determined from a solution of rhodamine 110 (10 nM). The rotational correlation time of eGFP (*φ)* was estimated from the loss of anisotropy (*r*) over time (t) according to [Equation 9](#equ10){ref-type="disp-formula"}, in which *r*(0) is the amplitude of the decay.$$r\left( \text{t} \right) = r\left( 0 \right)\left( exp\left( - \frac{t}{\varphi} \right) \right)$$

Where r0 is the is the decay amplitude and *ϕ* is the rotational correlation time.

Confocal imaging of intact CHO cells was performed on a Zeiss microscope (model LSM710) using a Plan-Apochromat oil-immersion objective lens (63×, 1.4 NA). Samples were irradiated at 488 nm and a power of 0.37 μW. An area of 134.7 × 134.7 μm^2^ was captured through a pinhole of 1 Airy unit, and each pixel in the image represented 0.26 μm^2^ according to the Nyquist theorem. A stack of 30 images was acquired at 5 nm intervals from 495 nm to 640 nm, and the data were processed through custom-written software in [M]{.ul}[[atlab]{.ul}]{.smallcaps} to obtain the emission spectrum corrected for background.

Individual spectra were unmixed by linear regression according to [Equation 10](#equ11){ref-type="disp-formula"} (two colors) or 11 (three colors), in which*k*~D~, *k*~A~, and *k*~B~, are the scaling factors for the contributions from FlAsH, mCherry, and eGFP, respectively.$$Y = k_{\text{D}}Em_{\text{D}} + k_{\text{A}}Em_{\text{A}}$$$$Y = k_{\text{B}}Em_{\text{B}} + k_{\text{D}}Em_{\text{D}} + k_{A}Em_{A}$$

The constants *Em*~D~ and *Em*~A~ represent the reference spectra for the donor (FlAsH) and acceptor (mCherry), respectively; *Em*~B~ represents the reference spectrum for eGFP, which was used as a marker for receptor with an intact orthosteric site when co-expressed with a binding-defective mutant.

The unmixed values of *k* for the donor (*k*~D~) and the acceptor (*k*~A~) were used to calculate the apparent FRET efficiency (*E*~app~) according to [Equation 12](#equ13){ref-type="disp-formula"} ([@bib21]; [@bib24]). In the case of *k*~A~, the fitted value from [Equation 10](#equ11){ref-type="disp-formula"} or [11](#equ12){ref-type="disp-formula"} was reduced by 6% to compensate for the direct excitation of mCherry at 498 nm.$$E_{\text{app}} = \frac{1}{1 + \frac{Q_{\text{A}}}{Q_{\text{D}}}\frac{k_{\text{D}}}{k_{\text{A}}}\frac{W_{\text{D}}}{W_{\text{A}}}}$$

The constants *Q*~D~ and *Q*~A~ represent the quantum yields, which were taken as 0.70 for the donor and 0.22 for the acceptor ([@bib30]); *W*~D~ and *W*~A~ are the corresponding spectral integrals, and the ratio of the regions between 495 and 640 (*W*~D~/*W*~A~) was computed from the reference spectra to be 0.94.

Kinetically determined mechanistic modeling {#s4-7}
-------------------------------------------

Time-dependent binding of an orthosteric ligand (L) to a monomeric receptor (R) was simulated according to [Figure 6](#fig6){ref-type="fig"}, in which access to and egress from the orthosteric site is precluded by an allosteric ligand (A). The system is defined by four ordinary differential equations ([Equation 13](#equ14){ref-type="disp-formula"}), which were solved numerically to obtain the amount of bound orthosteric ligand at different times (*i.e.*, \[RL\] + \[ARL\]). It was assumed that neither ligand is depleted through binding to the receptor, and the free concentrations in [Equation 13](#equ14){ref-type="disp-formula"} were taken as equal to the total concentrations. The simulations were performed in M[atlab]{.smallcaps} 2012b, and the integrals were calculated using the ODE23s subroutine.$$\begin{matrix}
\frac{d\lbrack RL\rbrack}{dt} & {= (k_{+ L}\lbrack R\rbrack\lbrack L\rbrack - k_{- L}\lbrack{RL}\rbrack) + (k_{- {AL}}\lbrack{ARL}\rbrack - k_{+ AL}\lbrack{RL}\rbrack\lbrack A\rbrack)} \\
\frac{d\lbrack AR\rbrack}{dt} & {= (k_{+ A}\lbrack R\rbrack\lbrack A\rbrack - k_{- A}\lbrack{AR}\rbrack)} \\
\frac{d\lbrack ARL\rbrack}{dt} & {= (k_{+ AL}\lbrack{RL}\rbrack\lbrack A\rbrack) - (k_{- {AL}}\lbrack{ARL}\rbrack)} \\
\frac{d\lbrack R\rbrack}{dt} & {= (k_{- L}\lbrack{RL}\rbrack - k_{+ L}\lbrack R\rbrack\lbrack L\rbrack) + (k_{- A}\lbrack{AR}\rbrack - k_{+ A}\lbrack R\rbrack\lbrack A\rbrack)} \\
\end{matrix}$$

The rate constants in [Equation 13](#equ14){ref-type="disp-formula"} were computed from the affinity constants according to [Equations 14--16](#equ15 equ16 equ17){ref-type="disp-formula"}, as described previously ([@bib28]).$$K_{\text{L}} = \frac{\text{[R][L]}}{\text{[RL]}} \equiv \frac{k_{- \text{L}}}{k_{+ \text{L}}}$$$$K_{\text{A}} = \frac{\text{[A][R]}}{\text{[AR]}} \equiv \frac{k_{\text{-A}}}{k_{+ \text{A}}}$$$$K_{\text{AL}} = \frac{\text{[A][RL]}}{\text{[ARL]}} \equiv \frac{k_{\text{-AL}}}{k_{+ \text{AL}}} \equiv \alpha K_{\text{A}}$$

Values of the cooperativity factor *α* were partitioned between the rate constants for association and dissociation according to [Equation 17](#equ18){ref-type="disp-formula"}. The value of *j* was 2 throughout.$$\frac{k_{\text{-AL}}}{k_{+ \text{AL}}} = \alpha\frac{k_{\text{-A}}}{k_{+ \text{A}}} \equiv \frac{\alpha^{j + 1}k_{\text{-A}}}{\alpha^{j}k_{+ \text{A}}} \equiv \frac{\left( \frac{1}{\alpha} \right)^{j}k_{\text{-A}}}{\left( \frac{\text{1}}{\alpha} \right)^{j + 1}k_{+ \text{A}}}$$

Molecular modeling and dynamics {#s4-8}
-------------------------------

Simulations were performed in the isothermal-isobaric (NPT) ensemble according to the Nosé-Poincaré-Andersen (NPA) equations of motion with a time-step of 2 fs. A cut-off of 10 Å was applied to non-bonding interactions. Equilibration was for 1 ns (300 K, harmonic restraints of 0.5 kcal mol^-1^ Å^-2^ applied to non-hydrogen atoms), and production continued for 30 ns (300 K, no restraints). Water molecules were wrapped, bond-lengths to lone-pairs, and hydrogen atoms were constrained. Systems were sampled, atomic coordinates saved, and snapshots taken every 2.5 ps. Images were rendered using either MOE or VMD.

### Construction of the model for mCh-M~2~-FCM {#s4-8-1}

Crystal structures of the M~2~ muscarinic receptor (4MQS, 4MQT) and mCherry (2H5Q) were obtained from the Protein Data Bank. The FlAsH-reactive sequence (FLNCCPGCCMEP) was incorporated into ECL2 of the receptor by homology modeling (Modeller 9.13). While modeling the loop, the rest of the protein was constrained to the crystallographic conformation. FlAsH was built in MOE 2013.08 (Molecular Operating Environment, 2014) and attached to the insertion sequence (CCPGCC) via covalent bonds between the sulfur atoms of the cysteine residues and the arsenic atoms of FlAsH. The length of the sulfur-to-arsenic bonds was set at 2.275 Å. Unresolved regions at the *C*-terminus of mCherry, the *N*-terminus of the receptor, and within the intracellular loop of the receptor between transmembrane domains 5 and 6 were modelled as described in Appendix 2

### Ligand--receptor and ligand--ligand interactions {#s4-8-2}

The structure of the receptor and the structures of orthosteric and allosteric ligands were computed as described in Appendix 2 . NMS or QNB was inserted at the orthosteric site by induced-fit docking using MOE, and the initial placement was guided by alpha spheres within 5 Å of iperoxo in 4MQS. The conformers generated previously for each ligand were docked using the Triangle Matcher placement method and the London dG initial scoring function. A post-placement force-field refinement then was carried out, allowing the receptor and the ligand to move freely within a cut-off distance of 10 Å for receptor-ligand interactions. Final poses were evaluated according to the GBVI/WSA dG scoring function. Structures were verified by superimposition on the 3UON crystal structure of the M~2~ receptor with QNB at the orthosteric site [@bib7]) guided by the essential interactions between the ligand and Asp^103^, Tyr^104^, Tyr^403^, Asn^404^, and Tyr^426^, as displayed in 4MQS and 3UON, and by comparison with the results of previous modeling studies ([@bib5]).

Strychnine or gallamine was inserted at the allosteric site in the manner described above for ligands at the orthosteric site. The site was defined by those amino acids in proximity with the allosteric ligand LY2119620 in the 4MQT structure. In the top-ranked poses, the cationic ammonium groups of strychnine and gallamine were oriented to interact with Tyr^177^ and Trp^422^. The second ammonium group of gallamine lay in the vicinity of Tyr^80^ and Tyr^83^, with the third ammonium group extending into solvent. There was no pose in which cationic groups interacted with the EDGE sequence of ECL2, although this interaction appeared during molecular dynamics simulations. The poses of gallamine and strychnine agreed with those obtained in previous simulations ([@bib5]).

The minimized structures of the vacant receptor and the eight complexes resulting from insertion of the four ligands were used as the starting points for molecular dynamics simulations in MOE. All atoms were represented explicitly using the CHARMM27 force field. Ligand-related parameters were checked using the CGenFF program on the CHARMM ParamChem server. Each system was solvated explicitly in a periodic box of TIP3P water molecules (approximately 12,800 molecules), neutralized with sodium chloride, and minimized to an RMS gradient of \<1.0 prior to simulation in MOE. The resulting system had approximately 45,800 atoms and a density of 1.009 g/cm^3^.

For each allosteric--orthosteric pair, the distance between their cationic nitrogen atoms was estimated according to Coulomb's law. In the case of gallamine, the nitrogen atom closest to that of the orthosteric ligand was selected. The electrostatic potential of an allosteric ligand in the absence and presence of an orthosteric ligand was calculated using the CHARMM27 force field, and the difference was taken as a measure of the energetic cost of repulsion. A degree of electrostatic repulsion was observed with all four ligand-pairs. The effect was observed throughout the simulations, but it diminished over time as the cations compensated by moving apart. In the case of strychnine and QNB, for example, the average difference in electrostatic potential was 0.7 kcal/mol over the first 10 ns of production and 0.06 kcal/mol over a period of 30 ns. Because the average electrostatic potential of the ligands over time does not scale directly with the degree of repulsion, the result of repulsion was tracked in terms of distance.
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Fluorophore-tagged variants of the M~2~ receptor {#s30}
================================================

To maximize the quantum yield of FlAsH, the tetracysteine motif was bracketed by the flanking sequences FLN and MEP ([@bib16]) (*i.e.*, FLNCCPGCCMEP, abbreviated FCM). The tripeptide FLN was added upstream of CCPGCC (forward primer, 5\'-CTCTTCTGGCAGTTCATTGTATTCTTGAACTGTTGCCCAGGATG-3\'), and MEP was added downstream of FLNCCPGCC (forward primer, 5\'-TGCCCAGGATGTTGCATGGAGCCGGGGGTGAGAACTGTG-3\') to obtain the construct designated mCh-M~2~-FCM.

To compare FlAsH with a fluorescent protein, mCherry was inserted in place of the FCM sequence after Val^166^ in ECL2 of the eGFP-tagged receptor.

Binding-defective mutants of the M~2~ receptor {#s31}
==============================================

Negatively charged residues in the EDGE sequence at positions 172--175 of ECL2 were replaced by positively charged residues (*i.e.*, Lys^172^Arg^173^Gly^174^Lys^175^) (forward primer, 5\'-CATTGTAGGGGTGAGAACTGTGAAGCGTGGGAAGTGCTACATTCAGTTTTTTTC-3\') in a receptor bearing hexahistidine at the *N*-terminus (*i.e.*, M~2~-ECL2+ve). Aspartic acid at position 103 was replaced by alanine (forward primer, 5\'-CTTTGGCTAGCCCTGGCCTATGTGGTCAGCAAT-3\') in a receptor bearing the FLAG epitope at the *N*-terminus \[*i.e.*, M~2~(D103A)\] and in the FRET-based sensor \[*i.e.*, mCh-M~2~(D103A)-FCM\].

*Sf*9 cells {#s32}
===========

The cells were cultured at 27 °C in Sf-900 II SFM insect cell medium supplemented with 2% fetal bovine serum, 1% Fungizone, and 50 μg/mL gentamycin (all from Gibco Life Technologies, Inc.). When growing at a density of 2 × 10^6^ cells/mL, they were infected with one or both baculoviruses at a total multiplicity of infection of 5.

CHO cells {#s33}
=========

Cells for transient transfections were grown in 5% CO~2~ at 37°C in Dulbecco's Modified Eagle's Medium (DMEM, Gibco Life Technologies, Inc.) supplemented with 10% fetal calf serum, 1% non-essential amino acids, 100 U/mL penicillin, and 100 μg/mL streptomycin (all from Gibco Life Technologies, Inc.). Transfections were performed on cells growing at 50--75% confluence. Cells intended for microscopy were grown in 35 mm dishes containing a No. 1.5 glass coverslip (Mattek), which served as a 14 mm microwell, and were transfected with 1 μg total DNA using 3 μL GeneExpresso Max transfection reagent (Excellgen). Cells otherwise were grown in T-175 tissue-culture flasks, transfected with 120 μg total DNA using 360 μL GeneExpresso Max reagent, harvested by scraping in phosphate-buffered saline (PBS, 20 mM KH~2~PO~4~, 150 mM NaCl, adjusted to pH 7.40 with NaOH), centrifuged for 10 min at 3,000 × *g* and 4 °C, and stored at −20 °C. In either case, two plasmids were transfected using equal amounts of DNA for each (*i.e.*, 0.5 μg or 60 μg). Frozen cells were thawed on ice as required and processed as described in Materials and Methods. 

Porcine atria {#s34}
=============

Briefly, fresh atria were washed twice with ice-cold PBS and homogenized in buffer B (20 mM imidazole, 1 mM EDTA, 0.1 mM PMSF, 0.02% NaN~3~, adjusted to pH 7.60 with HCl) supplemented with benzamidine (1 mM), pepstatin A (20 *µ*g/mL), leupeptin (0.2 *µ*g/mL), and bacitracin (200 *µ*g/mL). All constituents of PBS and buffer B were from Sigma-Aldrich. The resulting homogenate was fractionated by centrifugation on a sucrose density gradient (13--28%) to obtain the sarcolemmal fraction, which was collected by centrifugation, resuspended in buffer B, recovered by centrifugation, and stored at −70°C.

Electrophoresis and western blotting {#s35}
====================================

Samples were heated at 65°C for 5 min prior to loading on precast polyacrylamide gels from Bio-Rad (Ready Gel Tris-HCl, 10%). These conditions do not induce aggregation of the M~2~ muscarinic receptor from *Sf*9 cells. Resolved proteins were transferred onto nitrocellulose membranes (Bio-Rad, 0.45 *µ*m), treated for 2 hr with the primary antibody (anti-M~2~ muscarinic acetylcholine receptor monoclonal antibody, Thermoscientific) at a dilution of 1:1000, and then for 1 hr with the horseradish peroxidase-conjugated secondary antibody at a dilution of 1:3000. Proteins were visualized by chemiluminescence (ECL, Hyperfilm MP, GE Healthcare). The images were digitized at a resolution of 300 dpi, and the intensities of the bands were estimated from the densitometric trace using ImageJ ([@bib25]). Further details have been described previously ([@bib20]).

Solution of equations, optimization of parameters, and estimation of means and standard errors of the mean {#s36}
==========================================================================================================

All equations were fitted to the data according to the Levenberg-Marquardt procedure unless indicated otherwise [@bib15]). [Equation 3](#equ4){ref-type="disp-formula"} was solved numerically, as described previously ([@bib31]); other equations were solved analytically. Equilibrium constants and potencies in [Equations 2 and 3](#equ2 equ4){ref-type="disp-formula"} were optimized on a logarithmic scale; rate constants and other parameters were optimized throughout on a linear scale. The effects of various constraints on the weighted sum of squares were assessed by means of the *F*-statistic. Weighting of the data and other statistical procedures were performed as described previously ([@bib31]). In the case of parametric values derived from one set of data or from two or more sets in a global analysis, the errors were estimated from the diagonal elements of the covariance matrix ([Equations 1--3](#equ1 equ2 equ4){ref-type="disp-formula"}) or by bootstrapping ([Equations 6 and 9](#equ7 equ10){ref-type="disp-formula"}). Parametric values that are the means of independent estimates are presented together with the standard error unless stated otherwise. Further details of the analyses and statistical procedures have been described previously ([@bib28]; [@bib31]).

Modeling of unresolved regions at the *C*-terminus of mCherry, and the *N*-terminus and intracellular region of the receptor {#s37}
============================================================================================================================

Unresolved residues at the *C*-terminus of mCherry and the *N*-terminus of the M~2~ receptor (*i.e.*, mCh-GGMDELYKLE and NNSTNSSNNSLALTSPY-M~2~) were modeled using a LowModeMD conformational search conducted in MOE with the CHARMM27 force field. The resulting structures were joined, and the new system was subjected to steepest-descent minimization and refined by a short molecular dynamics simulation (5 ns) in a distance-dependent dielectric implicit model of solvation. A restraining distance of 55.7 Å was maintained between FlAsH and the center of the mCherry barrel, in accordance with the experimentally measured distance calculated from the FRET efficiency and the Förster radius. The intracellular region of the receptor between transmembrane domains 5 and 6 (*i.e.*, residues 233--374), which also is unresolved in 4MQS, was determined by homology modeling in Modeller 9.13 and protonated in MOE using the CHARMM27 force field at pH 7.0. The fusion product is shown in [Figure 2A](#fig2){ref-type="fig"}.

Ligand--receptor and ligand--ligand interactions {#s38}
================================================

Models of the receptor were based on crystal structures from which the G protein-mimetic nanobody (4MQS), the agonist iperoxo (M4QS), and the allosteric modulator LY2119620 (M4QT) were removed. Unresolved residues at the *N*- and *C*-termini were not included (*i.e.*, residues 1--18 and 457--466). Part of the intracellular region between transmembrane domains 5 and 6 also is unresolved (residues 233--374); the loop therefore was shortened to RIKKDKKEPVANQDPVSTRKK, which was modeled using Modeller 9.13. Five models of the loop were generated, with the rest of the protein constrained to its crystallographic conformation, and the structure with the lowest molpdf score was selected for subsequent simulations. The receptor, including the optimized third intracellular loop, then was protonated in MOE using the CHARMM27 force field at pH 7.0.

All orthosteric and allosteric ligands were built in MOE and protonated using the CHARMM27 force field at pH 7.0. A set of conformers was generated by means of LowModeMD, and force-field partial charges were calculated for each conformer. Those conformations whose energy exceeded the minimum by 9.0 kcal/mol or more were discarded.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your work entitled \"The Mechanistic Basis of Allosteric Modulation in a G Protein-coupled Receptor\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by Werner Kühlbrandt as the Reviewing Editor and Richard Aldrich as the Senior Editor.

The following individual involved in review of your submission has agreed to reveal their identity: Terry Hébert (peer reviewer).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The reviewers agree that this is a very solid article that follows on from previous work from your group demonstrating that receptor oligomerization is the basis of much of the ligand binding cooperativity in M~2~ muscarinic receptors. The manuscript combines a novel FRET approach based on spectral unmixing with molecular modelling and molecular dynamics simulations to understanding the nature of positive and negative cooperativity between orthosteric and allosteric sites in the receptor. As in previous work based on ligand binding in purified monomers or oligomers, you show that only negative cooperativity can be detected between the orthosteric and allosteric sites using a FlAsH-FRET approach. Using binding defective mutants you show that cooperativity between these two sites is lost but can be restored by an untagged WT receptor, suggesting that this allostery is rescued only in the context of an oligomeric receptor. The approach is elegant and the data is supported by your previous binding studies. The reviewers point out that your group has consistently provided the best proof for receptor oligomerization and its allosteric consequences. Nevertheless, they had a few substantive concerns they would like you to address.

Essential revisions:

1\) The title exaggerates the results dramatically and must be changed. The authors do not offer any molecular mechanism for how allosterism in an oligomer is propagated between receptors. The impact statement would make a far more accurate title.

2\) The authors claim they have validated the functionality of their modified receptors. This is critical for the measures of allosteric interactions to have any meaning and to be interpreted by the MD simulations. In fact, they only show that the core FlAsH-mCherry construct binds ligand in detergent. They claim that they can localize FlAsH binding to the cell surface but do not show this anywhere (not even in one of the copious supplemental figures). In the overexpression context, some receptor must be inside the cell so it would be good to see where the receptor is and when it binds FlAsH. They also do not show function in a cellular context. Interfering with ECL2 is potentially disruptive. In any case, this would need to be done for *all* their constructs (even the ones that don\'t bind) in order for us to interpret their results accurately.

3\) The authors claim that the anisotropy measurements demonstrate that the ECL2 moiety moves rather than the large GFP adduct. They show that is true under basal conditions, but what about in response to ligand? This is the only way to conclude that is doesn\'t move. Again, do these constructs need to be functional to interpret the data?

4\) How do the in-cell experiments prove allostery? Why can\'t this be molecular crosstalk? The authors should formally exclude this with a second receptor that does not dimerize with the M~2~ receptor -- or better yet measure the allostery in detergent-solubilized preps where crosstalk is not possible. They seem uniquely poised to do this.

5)In the first paragraph of the subsection "A FRET-based sensor of changes at the allosteric site" the authors mention that the affinity of the FRET-tagged receptor for NMS is unchanged, which is reassuring, but no data are shown for whether the extensively modified receptor used in the FRET experiments behaves in an identical fashion allosterically compared to the native receptor. This will require the purification of the tagged receptor, reconstitution into nanodiscs and liposomes and the experiments depicted in [Figure 1](#fig1){ref-type="fig"} repeated.

6)In the sixth paragraph of the subsection "A FRET-based sensor of changes at the allosteric site". The FRET efficiency was measured upon adding NMS alone, and then upon addition of NMS and gallamine together. The authors conclude that the change in FRET efficiency is due to the negative allosteric effect of gallamine, but do not do the control experiment of gallamine alone. This should be done.

7\) [Figure 2](#fig2){ref-type="fig"}. A full statistical analysis needs to be performed on the data in [Figures 2F](#fig2){ref-type="fig"} and [3D](#fig3){ref-type="fig"} to define the significance of the differences observed in each case.
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Author response

1\) The title exaggerates the results dramatically and must be changed. The authors do not offer any molecular mechanism for how allosterism in an oligomer is propagated between receptors. The impact statement would make a far more accurate title.

Although the original title referred only to 'mechanistic basis,' not 'molecular mechanism,' we have provided a new title that avoids such terms altogether (i.e., 'Allosteric modulation in monomers and oligomers of a G protein-coupled receptor').

2\) The authors claim they have validated the functionality of their modified receptors. This is critical for the measures of allosteric interactions to have any meaning and to be interpreted by the MD simulations. In fact, they only show that the core FlAsH-mCherry construct binds ligand in detergent. They claim that they can localize FlAsH binding to the cell surface but do not show this anywhere (not even in one of the copious supplemental figures). In the overexpression context, some receptor must be inside the cell so it would be good to see where the receptor is and when it binds FlAsH. They also do not show function in a cellular context. Interfering with ECL2 is potentially disruptive. In any case, this would need to be done for all their constructs (even the ones that don\'t bind) in order for us to interpret their results accurately.

Functionality of modified receptors. The original manuscript contained some information on the functionality of our modified receptors (points i and ii below), some of which was noted by the reviewers. We now have added additional data which we believe address their comment (points iii and iv).

i\) We and others have shown previously that the functionality of muscarinic receptors is not affected by the fusion of a fluorophore at the *N*-terminus of muscarinic receptors \[e.g., M~1~, Weill et al. (1999) J. Neurochem. 73, 791--801; M~2~, Pisterzi et al. (2010) J. Biol. Chem. 285, 16723--16738\]. This was noted originally in the Materials and methods, and it now appears in the Results (subsection "A FRET-based sensor of allosteric effects", second paragraph).

ii\) Two constructs contained modifications in the second extracellular loop (ECL2). In one case (i.e., M~2~-ECL2+), the negatively charged groups within the EDGE sequence (positions 172--175 in ECL2) were replaced by positively charged ones (i.e., [KR]{.ul}G[K]{.ul}) to reduce the affinity for gallamine at the allosteric site while retaining that for ligands at the orthosteric site. This mutant was co-expressed with a mutant possessing a defective orthosteric site \[i.e., M~2~(D103A)\], and the purified heteromer exhibited allosteric effects of high and intermediate affinity for gallamine that resembled those observed previously with the wild-type receptor. These observations demonstrate that the mutant retains some native functionality, and they identify that functionality as a property of oligomers. The data are presented in [Figure 3F](#fig3){ref-type="fig"} of the original and revised manuscripts.

iii\) The second construct contained a FlAsH-reactive insert in ECL2 and mCherry at the *N*-terminus (mCh-M~2~-FCM). We originally reported the affinity of solubilised mCh-M~2~-FCM for the antagonist *N*-\[^3^H\]methylscopolamine (NMS), as noted by the reviewers, but we did not assess its allosteric properties in binding assays. We now report that the binding of \[^3^H\]NMS to mCh-M~2~-FCM in CHO membranes and the modulation of that binding by the allosteric ligand gallamine are similar to what we reported previously for the wild-type receptor in CHO and myocardial membranes. The allosteric effect of gallamine is shown in [Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, and it demonstrates that the modified receptor retains the triphasic allosteric profile exhibited by the wild-type receptor. These results are introduced in the second paragraph of the subsection "A FRET-based sensor of allosteric effects.

iv\) Localisation. We mentioned originally that FlAsH-reacted receptors were localised at the plasma membrane and that there was little or no emission from the cytosol. As the reviewers noted, however, there were no images. The revised manuscript includes confocal images of all of the constructs used in the investigation: namely, mCh-M~2~-FCM, mCh-M~2~(D103A)-FCM and M~2~-FCM (all reacted with FlAsH) as well as eGFP-M~2~, mCh-M~2~ and eGFP-M~2~-mCh. None of the modifications impaired the ability of the receptor to localise at the membrane, nor was there an appreciable presence of receptors in the cytosol. These results are presented in the second paragraph of the subsection "A FRET-based sensor of allosteric effects" and in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} of the revised manuscript.

3\) The authors claim that the anisotropy measurements demonstrate that the ECL2 moiety moves rather than the large GFP adduct. They show that is true under basal conditions, but what about in response to ligand? This is the only way to conclude that is doesn\'t move. Again, do these constructs need to be functional to interpret the data?

The measurements of fluorescence anisotropy have been repeated for both of the constructs described in the original submission (i.e., eGFP-M~2~ and eGFP-truncM~2~). In addition, eGFP-M~2~ was examined in the presence of NMS, carbachol, gallamine and NMS + gallamine, as suggested by the reviewers, and we have performed our own measurements on eGFP alone. Finally, the rotational correlation times now are accompanied by the fluorescence lifetimes. These results are summarised in [Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}, Panel A.

Measurements of the liganded state of the receptor were performed only on the full-length construct (i.e., eGFP-M~2~). As noted above (point no. 2), we have shown previously that the wild-type M~2~ receptor remains functional when a fluorophore is fused at the *N*-terminus. The truncated receptor was designed to probe for any dependence of the correlation time on the length of the link to the fluorophore. It was not examined for its allosteric properties, and it therefore seems unnecessary to measure its anisotropy in the liganded state.

Conclusions drawn from the rotational correlation times are the same as before, but the details are somewhat different from those described previously. In particular, the rapidly decaying (*φ* \< 1 ns), minor component of the signal is no longer observed, and the anisotropy can be described by one exponential rather than two. The difference is due in part to a longer averaging time, giving a higher signal-to-noise ratio, and in part to improvements in the method of analysis. The fluorescence decay traces from the horizontal and vertical channels now are fit simultaneously upon deconvolution of the instrument response function assuming a mono-exponential decay of the intensity and another exponential term that defines the rotational correlation time. This leads to concurrent estimates of the fluorescence lifetime and the rotational correlation lifetime, and it provides a basis for distinguishing between free eGFP on the one hand and the eGFP-tagged receptors on the other.

4\) How do the in-cell experiments prove allostery? Why can\'t this be molecular crosstalk? The authors should formally exclude this with a second receptor that does not dimerize with the M~2~ receptor -- or better yet measure the allostery in detergent-solubilized preps where crosstalk is not possible. They seem uniquely poised to do this.

We believe that the results of the in-cell experiments argue persuasively for allostery between interacting protomers, as do those of the binding assays. Whether or not they arise from molecular cross-talk depends in part on one's understanding of that term.

In our experiments, the intermolecular component of allostery has been confirmed directly -- i.e., at the level of the receptor -- using binding assays and FRET. The wild-type receptor was co-expressed with a mutant of the FRET sensor lacking the orthosteric site to demonstrate that binding of NMS to the former increased the FRET efficiency at the latter ([Figures 3C and D](#fig3){ref-type="fig"}). The effect was repeated using an eGFP-tagged wild-type receptor and selecting only those cells that co-expressed both fluorophores i.e., eGFP on the wild-type receptor and mCherry on FlAsH-reacted mCh-M~2~(D103A)-FCM ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}; subsection "Intermolecular modulation of FRET", last paragraph). We also purified a heteromer of two mutants, one lacking the orthosteric site \[i.e., FLAG-M~2~(D103A)\] and one lacking the allosteric site (i.e., His6-M~2~-ECL2+ve; see also point no. 2iii above), and demonstrated that high-affinity effects of gallamine on the binding of \[^3^H\]NMS are a manifestation of interactions between the allosteric site of one protomer and the orthosteric site of another ([Figure 3F](#fig3){ref-type="fig"}). These data point directly to allosteric interactions between two or more molecules of receptor.

Cross-talk often is used to describe the downstream convergent effects of two proteins that regulate or otherwise participate in the same signalling pathway. Related to this idea is the notion of a transient interaction between one protein and a third party that affects its interaction with a second protein. Finally, one can imagine something akin to a scaffold that would mediate between two proteins. The reviewers' reference to studies in a solubilised preparation suggests to us that they are referring to the first or second of these interpretations. Both possibilities are difficult to reconcile with the results from any one of the experiments described above, and they seem highly unlikely in the light of all three. Also, the third experiment described above is in effect one of those recommended by the reviewers.

The notion of an unidentified third party acting as an intermediary in a stable ternary complex is more difficult to reject categorically, inasmuch as it could exist in the intact CHO cells (FRET) and survive purification (binding). We have studied purified and reconstituted M~2~ receptors at some length over the years, however, and we have no evidence that such a third party is present in oligomers or necessary for their existence. Given that such an arrangement seems speculative and unlikely, we have opted not to consider it in the present manuscript. This of course could be revisited if the reviewers think otherwise.

5\) In the first paragraph of the subsection "A FRET-based sensor of changes at the allosteric site" the authors mention that the affinity of the FRET-tagged receptor for NMS is unchanged, which is reassuring, but no data are shown for whether the extensively modified receptor used in the FRET experiments behaves in an identical fashion allosterically compared to the native receptor. This will require the purification of the tagged receptor, reconstitution into nanodiscs and liposomes and the experiments depicted in [Figure 1](#fig1){ref-type="fig"} repeated.

This comment seems to concern the same issue as that in point no. 2, which we have addressed experimentally as described above (point no. 2iii). In addition, however, the reviewers suggest that the experiments of [Figure 1](#fig1){ref-type="fig"} be repeated on the mCherry- and FCM-modified receptor after its reconstitution in nanodiscs and liposomes. The reviewers evidently were thinking of our recent paper in which we compared the M~2~ receptor reconstituted as a monomer in nanodiscs and as a reassembled tetramer in liposomes \[Redka et al. (2014)J. Biol. Chem. 289, 24347--24365\].

We have not undertaken such experiments, which in our view would not warrant the very substantial commitment of time and resources. A baculovirus would have to be prepared, large quantities of the monomeric protein would have to be purified from *Sf*9 cells, the purified monomers would have to be reconstituted as monomers in nanodiscs and as tetramers in liposomes, and the two preparations would have to be characterised for their binding properties. The oligomeric state of the receptor would have to be confirmed at each step. All of this would take several months, which would put us well beyond the period allowed for revisions, and it would increase substantially the length of an already lengthy manuscript. It would be, in effect, a new investigation.

The reviewers have suggested that such an investigation is required to confirm that the allosteric properties of the wild-type receptor are not affected by the modification. We believe, however, that this is demonstrated adequately by the present data. As noted by the reviewers, we reported in the original submission that the affinity of \[^3^H\]NMS for the wild-type and modified receptors was the same. We now have shown that, in membranes from CHO cells, the modified receptor displays the characteristic triphasic effect of gallamine on the binding of \[^3^H\]NMS. We see that as persuasive evidence for the retention of the allosteric properties.

A further consideration here is that, in our view, recovery of the triphasic profile in reconstituted tetramers would do little to validate the nature of the receptor in CHO membranes; rather, it would demonstrate that reconstituted tetramers of the modified receptor have recovered the native allosteric properties. That would be of interest if one were planning experiments on reconstituted tetramers, and it certainly would support our claim that reconstituted tetramers are a faithful reconstruction of the native state \[Ma et al. (2007) Biochemistry 46, 7907--7927; Redk aet al. (2013) Biochemistry 52, 7405--7427; Redka et al. (2014) ibid.\], but those issues are beyond the scope of the present manuscript. If the native allosteric properties were not recovered upon reconstitution of the mutant in liposomes, it would raise questions about the nature of that reconstituted preparation, but it would not invalidate our conclusions regarding the modified receptor in CHO membranes or whole cells.

Finally, there is the question of reconstituting monomers in nanodiscs. This also would be a time-consuming exercise that seems to offer little if any gain. It is clear from the present data that all of the complexity represented by the triphasic, serpentine binding curves is absent from monomers in solution, which behave as one would expect for a single orthosteric site and a single allosteric site on the same protomer. When we compare affinities, it is between the single affinity of gallamine or strychnine for monomers in solution and the affinities for oligomers in solution. It is not clear to us how the story would be advanced by measurements on monomers in nanodiscs. Also, the binding of agonists and antagonists to monomers is essentially the same in solution and after reconstitution in nanodiscs \[e.g., Redka et al. (2014) ibid.\]. It seems reasonable to suppose that the same would be true of intramolecular allosteric effects.

6\) In the sixth paragraph of the subsection "A FRET-based sensor of changes at the allosteric site". The FRET efficiency was measured upon adding NMS alone, and then upon addition of NMS and gallamine together. The authors conclude that the change in FRET efficiency is due to the negative allosteric effect of gallamine, but do not do the control experiment of gallamine alone. This should be done.

The assays with gallamine have been performed, and the results have been included in the revised manuscript (subsection "A FRET-based sensor of allosteric effects", seventh paragraph; [Figure 2F](#fig2){ref-type="fig"} (now 2E), [Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}, Panel F).

7\) [Figure 2](#fig2){ref-type="fig"}. A full statistical analysis needs to be performed on the data in [Figures 2F](#fig2){ref-type="fig"} and [3D](#fig3){ref-type="fig"} to define the significance of the differences observed in each case.

Statistical details pertaining to the data in [Figures 2F](#fig2){ref-type="fig"} (now 2E) and 3D are now shown in [Figure 2---source data 1](#SD4-data){ref-type="supplementary-material"}, Panel F and [Figure 3---source data 1](#SD5-data){ref-type="supplementary-material"}.

[^1]: Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States.

[^2]: Department of Computer Science, Stanford University, Stanford, United States.

[^3]: *^a^* The distances are shown in [Figures 4A and B](#fig4){ref-type="fig"}.
